[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 5762
1. Hanyu K, Iida T, Shiba H, Ohashi T, Eto Y, Yanaga K: Immunogene therapy by adenovirus vector expressing CD40 ligand for metastatic liver cancer in rats. Anticancer Res; 2008 Sep-Oct;28(5A):2785-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunogene therapy by adenovirus vector expressing CD40 ligand for metastatic liver cancer in rats.
  • BACKGROUND: We have explored a gene-therapeutic approach to stimulate antitumor immunity by adenoviral-mediated transfer of CD40 ligand (CD40L) to treat metastatic liver cancer in a rat model.
  • MATERIALS AND METHODS: Rat metastatic liver cancer cells were implanted into the back of rats bilaterally.
  • When the larger tumor reached 8.0 mm in diameter, adenovirus vector-expressing mouse CD40L was injected intratumorally as treatment group (n=5), while LacZ was injected in the control group (n=5).
  • RESULTS: In the control group, the tumor gradually grew to be 20.7+/-1.6 (mean+/-SD) mm in intratumorally injected tumors and 21.8+/-3.7 mm in opposite tumors seven weeks after injection, respectively.
  • In contrast, in the treatment group, the tumor was reduced to 3.6+/-8.2 mm and 3.7+/-8.2 mm.
  • The tumor growth and survival rate were significantly different (p<0.001).
  • CONCLUSION: Adenovirus vector-mediated CD40L gene therapy is an effective therapeutic method for metastatic liver cancer.
  • [MeSH-major] CD40 Ligand / genetics. CD40 Ligand / immunology. Immunogenetics / methods. Liver Neoplasms, Experimental / immunology. Liver Neoplasms, Experimental / therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035311.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 147205-72-9 / CD40 Ligand
  •  go-up   go-down


2. Matera L, Galetto A, Bello M, Baiocco C, Chiappino I, Castellano G, Stacchini A, Satolli MA, Mele M, Sandrucci S, Mussa A, Bisi G, Whiteside TL: In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma. J Transl Med; 2006;4:49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma.
  • BACKGROUND: Besides being the effectors of native anti-tumor cytotoxicity, NK cells participate in T-lymphocyte responses by promoting the maturation of dendritic cells (DC).
  • Adherent NK (A-NK) cells constitute a subset of IL-2-stimulated NK cells which show increased expression of integrins and the ability to adhere to solid surface and to migrate, infiltrate, and destroy cancer.
  • A critical issue in therapy of metastatic disease is the optimization of NK cell migration to tumor tissues and their persistence therein.
  • This study compares localization to liver metastases of autologous A-NK cells administered via the systemic (intravenous, i.v.) versus locoregional (intraarterial, i.a.) routes.
  • PATIENTS AND METHODS: A-NK cells expanded ex-vivo with IL-2 and labeled with (111)In-oxine were injected i.a. in the liver of three colon carcinoma patients.
  • Migration of these cells to various organs was evaluated by SPET and their differential localization to normal and neoplastic liver was demonstrated after i.v. injection of 99mTc-phytate.
  • When injected i.v., these cells localized to the lung before being visible in the spleen and liver.
  • By contrast, localization of i.a. injected A-NK cells was virtually confined to the spleen and liver.
  • Binding of A-NK cells to liver neoplastic tissues was observed only after i.a. injections.
  • CONCLUSION: This unique study design demonstrates that A-NK cells adoptively transferred to the liver via the intraarterial route have preferential access and substantial accumulation to the tumor site.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 2000 Jan;48(10):550-60 [10630307.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):281-9 [7995947.001]
  • [Cites] J Exp Med. 2001 Jan 15;193(2):233-8 [11208863.001]
  • [Cites] Curr Opin Immunol. 2001 Apr;13(2):154-62 [11228407.001]
  • [Cites] Am J Clin Oncol. 2001 Aug;24(4):354-9 [11474260.001]
  • [Cites] Trends Immunol. 2001 Nov;22(11):633-40 [11698225.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):327-33 [11828007.001]
  • [Cites] J Exp Med. 2002 Feb 4;195(3):335-41 [11828008.001]
  • [Cites] J Exp Med. 2002 May 20;195(10):1279-88 [12021308.001]
  • [Cites] Immunol Rev. 2001 Dec;184:236-43 [12086316.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):957-64 [12461568.001]
  • [Cites] Gut. 2003 Feb;52(2):307-14 [12524419.001]
  • [Cites] J Exp Med. 2003 Apr 21;197(8):967-76 [12695488.001]
  • [Cites] Immunity. 2003 Oct;19(4):561-9 [14563320.001]
  • [Cites] Anticancer Drugs. 2003 Nov;14(10):833-43 [14597879.001]
  • [Cites] Trends Immunol. 2004 Jan;25(1):47-52 [14698284.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):1009-17 [14707074.001]
  • [Cites] Cytotherapy. 2004;6(1):15-22 [14985163.001]
  • [Cites] Annu Rev Immunol. 2004;22:405-29 [15032583.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4779-89 [15067054.001]
  • [Cites] Eur J Immunol. 2004 May;34(5):1333-41 [15114666.001]
  • [Cites] Stem Cells Dev. 2004 Jun;13(3):307-14 [15186726.001]
  • [Cites] J Exp Med. 2004 Jun 21;199(12):1607-18 [15197224.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1861-71 [15274367.001]
  • [Cites] Eur J Immunol. 2004 Sep;34(9):2529-40 [15307185.001]
  • [Cites] J Immunother. 2004 Sep-Oct;27(5):398-404 [15314549.001]
  • [Cites] Curr Mol Med. 2004 Jun;4(4):431-8 [15354873.001]
  • [Cites] J Leukoc Biol. 2004 Dec;76(6):1187-99 [15356097.001]
  • [Cites] Blood. 2005 Jan 1;105(1):178-85 [15367435.001]
  • [Cites] J Exp Med. 1990 May 1;171(5):1527-33 [2139697.001]
  • [Cites] Immunol Rev. 2000 Apr;174:5-20 [10807503.001]
  • (PMID = 17105663.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1681349
  •  go-up   go-down


3. Nikfarjam M, Muralidharan V, Malcontenti-Wilson C, Christophi C: The apoptotic response of liver and colorectal liver metastases to focal hyperthermic injury. Anticancer Res; 2005 Mar-Apr;25(2B):1413-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The apoptotic response of liver and colorectal liver metastases to focal hyperthermic injury.
  • BACKGROUND: Ablation of liver tumours by focal hyperthermia causes tissue injury not only by direct effects, but also by progressive tissue damage following the initial heat application.
  • The role of apoptosis in the subsequent progression of focal hyperthermia injury was investigated in liver and colorectal liver metastases in a murine model.
  • MATERIALS AND METHODS: Focal hyperthermia produced by laser (Nd-YAG--wavelength 1064 nm) was applied to the liver and colorectal liver metastases in CBA mice (2 Watts for 50 seconds).
  • The sequence of the apoptotic response was determined at the treated tissue margins and compared to untreated liver and tumour.
  • RESULTS: Focal hyperthermia produced progressive tissue injury in both liver and colorectal liver metastases.
  • CONCLUSION: Increased apoptosis occurs following the application of focal hyperthermia to normal liver and colorectal metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hyperthermia, Induced. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865099.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


Advertisement
4. Garcia-Conde M, Roldan-Delgado H, Martel-Barth-Hansen D, Manzano-Sanz C: Anaplastic transformation of an atypical intraventricular meningioma with metastases to the liver: case report. Neurocirugia (Astur); 2009 Dec;20(6):541-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic transformation of an atypical intraventricular meningioma with metastases to the liver: case report.
  • OBJECTIVE: Malignant intraventricular meningiomas are very rare.
  • Seven of them developed cerebrospinal fluid (CSF) metastases.
  • We present herein the first case of a malignant intraventricular meningioma with extraneural metastases.
  • Thereafter, the tumor recurred twice.
  • At first recurrence, the tumor was completely removed again and external radiotherapy was administered.
  • At surgery at second recurrence, the tumor was more aggressive, invading the brain parenchyma.
  • Abdominal ultrasound examination disclosed multiple hypoechoic liver lesions.
  • Biopsy was consistent with liver metastases of a malignant meningioma.
  • The patient died of acute liver failure seven months after initial diagnosis.
  • CONCLUSION: Malignant intraventricular meningiomas are prone to recur and develop metastases, mainly through the CSF.
  • Nevertheless, our case shows that extraneural metastases are also possible.
  • Therefore, when systemic deterioration occurs in a patient with a malignant intraventricular meningioma, metastases to extraneural organs such as the liver must be ruled out.
  • [MeSH-major] Anaplasia / pathology. Liver Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19967319.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


5. Yeom JO, Yoon SB, Kim JG, Oh JH, Jeon EJ, Jeong JJ, Choi SW, Lee S: [A case of hepatocellular carcinoma combined with liver abscess]. Korean J Gastroenterol; 2009 Jun;53(6):378-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hepatocellular carcinoma combined with liver abscess].
  • Hepatocellular calcinoma (HCC) is the fifth most common cancer and the third leading cause of cancer-related deaths worldwide.
  • But, the clinical presentations and radiologic findings of liver abscess, HCC, and metastatic tumor to the liver may be quite similar, and procedures such as serum tumor marker assay, computerized tomography, and ultrasonography of the liver cannot make a specific diagnosis.
  • We report a case of HCC successfully diagnosed by surgery which was misconceived as liver abscess and not improved by medical treatment.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Abscess / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Humans. Liver / diagnostic imaging. Male. Middle Aged. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19556846.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


6. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, Kong LQ, Wang L, Wu WZ, Tang ZY: Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res; 2010 Jul 1;16(13):3420-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
  • PURPOSE: To investigate the role of macrophages in tumor progression under sorafenib treatment and to explore whether combination of drugs that deplete macrophages improved the antitumor effect of sorafenib.
  • EXPERIMENTAL DESIGN: Tumor growth, lung metastasis, and tumor angiogenesis were observed in HCCLM3-R and SMMC7721, two human hepatocellular carcinoma xenograft nude mouse models, when treated with sorafenib (30 mg/kg daily, n = 6 per group) or a vehicle as control.
  • Macrophage infiltration was measured in the peripheral blood and in sorafenib-treated tumor by immunohistochemistry and flow cytometry with F4/80 antibody and CD11b antibody.
  • The effect of macrophage depletion on tumor angiogenesis and metastasis after sorafenib treatment, using two drug target macrophages, zoledronic acid (ZA) and clodrolip, was measured in the two models of hepatocellular carcinoma.
  • RESULTS: Although sorafenib significantly inhibited tumor growth and lung metastasis, it induced a significant increase in peripheral recruitment and intratumoral infiltration of F4/80- and CD11b-positive cells, which was accompanied with elevation of colony-stimulating factor-1, stromal-derived factor 1alpha, and vascular endothelial growth factor in the tumor and elevation of plasma colony-stimulating factor-1 and mouse vascular endothelial growth factor in peripheral blood, suggesting the role of macrophages in tumor progression under sorafenib treatment.
  • Depletion of macrophages by clodrolip or ZA in combination with sorafenib significantly inhibited tumor progression, tumor angiogenesis, and lung metastasis compared with mice treated with sorafenib alone.
  • CONCLUSIONS: Macrophages may have an important role in tumor progression under sorafenib treatment.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms, Experimental / drug therapy. Macrophages / immunology. Pyridines / therapeutic use
  • [MeSH-minor] Animals. Cell Line, Tumor. Clodronic Acid / pharmacology. Diphosphonates / pharmacology. Drug Therapy, Combination. Humans. Imidazoles / pharmacology. Liposomes / pharmacology. Lung Neoplasms / prevention & control. Lung Neoplasms / secondary. Male. Mice. Mice, Nude. Niacinamide / analogs & derivatives. Phenylurea Compounds. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20570927.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Benzenesulfonates; 0 / Diphosphonates; 0 / Imidazoles; 0 / Liposomes; 0 / Phenylurea Compounds; 0 / Pyridines; 0813BZ6866 / Clodronic Acid; 25X51I8RD4 / Niacinamide; 6XC1PAD3KF / zoledronic acid; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


7. Maluccio M, Einhorn LH, Goulet RJ: Surgical therapy for testicular cancer metastatic to the liver. HPB (Oxford); 2007;9(3):199-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical therapy for testicular cancer metastatic to the liver.
  • In recent years improved cure rates have been achieved for testicular cancer.
  • A better understanding of the biology of subtypes of testicular cancer and the introduction of surgical intervention has contributed greatly to how we currently approach a young man with testicular cancer.
  • We describe here experience at our institution of the treatment, results and prognostic factors for testicular cancer metastases to the liver.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1999 Oct-Nov;6(7):640-4 [10560848.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):171-5 [10926798.001]
  • [Cites] Adv Surg. 2000;34:351-81 [10997228.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):643-50 [11034240.001]
  • [Cites] CA Cancer J Clin. 1999 Jul-Aug;49(4):231-55 [11198884.001]
  • [Cites] Urology. 1994 Jan;43(1):74-80 [7506856.001]
  • [Cites] Eur Urol. 2003 Aug;44(2):233-44 [12875944.001]
  • [Cites] BJU Int. 2004 Sep;94(4):552-8 [15329111.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):650-4 [15350354.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):269-76 [15650637.001]
  • [Cites] Ann Surg. 1990 Sep;212(3):290-3; discussion 293-4 [2168694.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4592-5 [11904381.001]
  • (PMID = 18333222.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063601
  •  go-up   go-down


8. Mielczarek M, Chrzanowska A, Scibior D, Skwarek A, Ashamiss F, Lewandowska K, Baranczyk-Kuzma A: Arginase as a useful factor for the diagnosis of colorectal cancer liver metastases. Int J Biol Markers; 2006 Jan - Mar;21(1):40-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Arginase as a useful factor for the diagnosis of colorectal cancer liver metastases.
  • : The present work is a continuation of studies on arginase as a marker in the diagnosis of colorectal cancer liver metastases (CRCLM).
  • The purpose of the study was the evaluation of the arginase test in comparison with other colorectal cancer tests such as CEA, CA 19-9 and biochemical markers of liver function such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT).
  • The studies were conducted on blood serum from 85 patients with CRCLM obtained one to two days before tumor resection.
  • The control group comprised 140 healthy blood donors and 81 patients with various non-malignant gastrointestinal diseases.
  • It can thus be concluded that the determination of serum arginase activity can be helpful in the diagnosis of patients with colorectal cancer liver metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28207092.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


9. Sadaba LM, Garcia-Layana A, Garcia-Gomez PJ, Salinas-Alaman A: Sarcomatoid carcinoma and orbital apex syndrome. Eur J Ophthalmol; 2006 Jul-Aug;16(4):608-610
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A biopsy was performed and immunohistochemistry was used to confirm the diagnosis of the tumor.
  • Eight months later, the patient presented with bone and liver metastases, and he died 4 months later.
  • CONCLUSIONS: Sarcomatoid carcinoma is an aggressive tumor that can produce compressive symptoms with very poor visual and survival prognoses.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28221641.001).
  • [ISSN] 1724-6016
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Halama J, Neoral C, Klos D: [Unusual approach to a liver metastasis resection]. Rozhl Chir; 2010 Sep;89(9):461-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual approach to a liver metastasis resection].
  • [Transliterated title] Neobvyklý prístup k resekci metastázy jater.
  • Metastatic disorder is a common finding in patients with abdominal tumors.
  • This case review presents a case of a 52-year old female with a forth relapse of her liver metastasis in the liver segment VIII.
  • In the current procedure, the authors opted for a thoracic transdiaphragmatic approach, which provided perfect view of the site in order to remove the metastasis in the liver segment VIII with partial excision of the adjacent diaphragm.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121157.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


11. Liapi E, Geschwind JF: Chemoembolization for primary and metastatic liver cancer. Cancer J; 2010 Mar-Apr;16(2):156-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoembolization for primary and metastatic liver cancer.
  • Transcatheter arterial chemoembolization (TACE) is one of the most commonly performed procedures in interventional radiology and is currently used for the palliative treatment of primary and metastatic hepatic malignancies.
  • In this article, we will review some technical components, patient selection, current results, and future directions of TACE and TACE with drug-eluting microspheres for primary and metastatic liver cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chemoembolization, Therapeutic. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20404613.001).
  • [ISSN] 1540-336X
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


12. Inoue T, Kudo M: [Radio frequency ablation for metastatic liver cancer]. Gan To Kagaku Ryoho; 2009 Aug;36(8):1253-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radio frequency ablation for metastatic liver cancer].
  • RFA has been used as a new therapeutic tool for metastatic liver cancer.
  • We describe the present situation in our institution regarding RFA therapy for metastatic liver cancer originating from colorectal carcinoma.
  • [MeSH-major] Catheter Ablation / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692763.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Zhang K, Tang W, Qu X, Guo Q, Inagaki Y, Seyama Y, Abe H, Gai R, Kokudo N, Sugawara Y, Nakata M, Makuuchi M: KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma. Hepatogastroenterology; 2009 Jul-Aug;56(93):960-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma.
  • This study aimed to assess subcellular localization of KL-6 mucin in liver metastatic tissues from colorectal carcinoma and hepatocellular carcinoma tissues.
  • METHODOLOGY: Tissue samples were collected from 56 patients with liver metastasis of colorectal carcinoma and 92 patients with hepatocellular carcinoma who underwent a hepatectomy.
  • RESULTS: All 56 cases with metastatic liver cancer showed positive staining for KL-6 mucin in cancer tissues but not in non-cancerous tissues.
  • All staining was observed in the circumferential membrane and/or cytoplasm of the cancer cells.
  • CONCLUSIONS: KL-6 mucin may be an indicator for liver metastasis of colorectal carcinoma.
  • Additionally, detection of KL-6 mucin may be helpful in distinguishing hepatocellular carcinoma from metastatic liver cancer.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Carcinoma, Hepatocellular / metabolism. Colorectal Neoplasms / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Mucin-1 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged


14. Miao N, Pingpank JF, Alexander HR, Steinberg SM, Beresneva T, Quezado ZM: Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol; 2008 Mar;15(3):815-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous hepatic perfusion in patients with metastatic liver cancer: anesthetic, hemodynamic, and metabolic considerations.
  • BACKGROUND: Percutaneous hepatic perfusion (PHP), a regional cancer therapy, entails insertion of percutaneous catheters to isolate hepatic vasculature and enable simultaneous hepatic venous hemofiltration of high-dose chemotherapy.
  • PHP has been shown to be safe and to benefit some patients with liver metastases.
  • METHODS: We examined hemodynamic and metabolic changes as well as anesthetic implications during PHP in patients with metastatic liver cancer enrolled in clinical trials of escalating doses of melphalan between 2001 and 2006.
  • Diagnoses included neuroendocrine tumors, melanoma, and metastatic carcinomas.
  • Based upon available data derived from all procedures, incorporating multiple procedures per patient, after occlusion of the inferior vena cava and during hepatic perfusion, there were decreases in mean arterial (-15.4 +/- 1 and -7.4 +/- 1 mmHg, respectively) and central venous pressure (-5.4 +/- 0.3 and -5.6 +/- 0.3 mmHg) and increases in heart rate (11 +/- 1 and 13.4 +/- 0.9 bpm) (all p < 0.0001) which resolved with completion of the procedure.
  • During hepatic perfusion with melphalan, compared to baseline, there were decreases in pH (-0.09 +/- 0.01) and bicarbonate (-3.3 +/- 0.6 mmol/L) (both p < 0.0001) and, upon completion of procedure, increases (2.6 +/- 0.4 mmol/L) in bicarbonate, compared to values during hepatic perfusion (p < 0.0001).
  • In order to assure patient comfort and facilitate timely diagnosis and treatment of associated hemodynamic and metabolic changes, we favor administration of general anesthesia, rather than sedation, for patients undergoing PHP.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Liver Neoplasms / drug therapy. Melphalan / administration & dosage

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180999.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q41OR9510P / Melphalan
  •  go-up   go-down


15. Nanashima A, Shibata K, Nakayama T, Tobinaga S, Araki M, Kunizaki M, Takeshita H, Hidaka S, Sawai T, Nagayasu T, Yasutake T: Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma. Ann Surg Oncol; 2009 Aug;16(8):2130-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma.
  • We investigated whether MVC assessed by staining with CD34 antibody was associated with disease-free and overall survival in patients with metastatic liver cancer (MLC).
  • By means of the modern Japanese classification of liver metastasis, poorer survival was associated with higher score, poorly differentiated adenocarcinoma, higher preoperative carcinoembryonic antigen (CEA) level, fibrous pseudocapsular formation, and smaller surgical margin.
  • Shorter disease-free survival was associated with higher score when the Japanese classification of liver metastasis was used, multiple or bilobar tumor, regional lymph node metastasis in primary colon carcinoma, preoperative CEA level, fibrous pseudocapsular formation, and smaller surgical margin (<5 mm).
  • CONCLUSIONS: Tumor MVC seems to be a useful prognostic marker of MLC patient survival.
  • [MeSH-major] Adenocarcinoma / blood supply. Colorectal Neoplasms / blood supply. Liver Neoplasms / blood supply. Microvessels / pathology. Neoplasm Recurrence, Local / blood supply
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Female. Follow-Up Studies. Hepatectomy. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Microcirculation. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome. Young Adult


16. Horiuchi H, Uchida S, Hisaka T, Ishikawa H, Sakai T, Kawahara R, Kinoshita H, Shirouzu K: [A study of recurrent pancreatic cancer with metastatic liver tumors after pancreatectomy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1685-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A study of recurrent pancreatic cancer with metastatic liver tumors after pancreatectomy].
  • BACKGROUND: Pancreatectomy is the best treatment for pancreatic cancer.
  • However, there is a high risk of post-operative complications, such as local recurrence, metastatic lymphadenopathy, carcinomatosa peritonitis and liver metastasis.
  • Presently, there is no significant treatment that has yet had a strong impact on recurrent pancreatic cancer.
  • This study was conducted concerning recurrent pancreatic cancer with metastatic liver tumors after pancreatectomy.
  • SUBJECTS AND METHODS: Between April 1998 and March 2005, our institute treated recurrent pancreatic cancer patients with liver metastasis.
  • RESULTS: Nine cases had a recurrent pancreatic cancer with metastatic liver tumors.
  • CONCLUSIONS: Prolongation of the survival period was obtained by administration of GEM for recurrent pancreatic cancer with metastatic liver tumors and inoperable advanced pancreatic cancer.
  • We attempted to utilize the active treatment for recurrent pancreatic cancer with metastatic liver tumors.
  • Thus, it was indicated that the therapy can be effective against recurrent pancreatic cancer with metastatic liver tumors.
  • [MeSH-major] Liver Neoplasms / secondary. Pancreatectomy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate


17. Di Battista M, Saponara M, Pantaleo MA, Catena F, Santini D, Lolli C, Di Scioscio V, Astorino M, Maleddu A, Nannini M, Biasco G: Microscopic margins of resection in gastrointestinal stromal tumor (GIST): An analysis of 122 patients. J Clin Oncol; 2009 May 20;27(15_suppl):10554
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic margins of resection in gastrointestinal stromal tumor (GIST): An analysis of 122 patients.
  • The prognosis is strongly correlated with both tumor size and mitotic index.
  • RESULTS: All patients but one, had a c-Kit positive GIST, 91% had primary disease without metastasis, 9% had metastasis.
  • The most common sites of tumor origin were the stomach (54.9%) and the small bowel (36.9%).
  • Sites of tumor metastasis were liver (18.2%), peritoneum (36.4%) or both (19.3%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963950.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Maximous D, Abdel-Wanis ME, Aboziada MA, El-Sayed MI, Abd-Elsayed AA: Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15677
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15677 Background: Almost 30% of patients with pancreatic cancer present with locally advanced tumours in absence of distant metastasis.
  • The combination of gemcitabine with concurrent radiation therapy is a promising approach that is being investigated in patients' unresectable pancreatic cancer.
  • AIM OF THE WORK: The efficacy of preoperative gemcitabine based chemo-radiotherapy in increasing the resectability rate for patients locally advanced, non metastatic pancreatic cancer was assessed.
  • RESULTS: Patients who achieved complete remission (CR) were 2 out of 25 patients while those achieved partial remission (PR) were 11 out of 25, 6 of them were considered operable.
  • Out of 8 patients who underwent radical surgical resection, only one patient developed local recurrence and simultaneous liver metastasis during the follow up period.
  • CONCLUSIONS: preoperative gemcitabine based chemoradiation might benefit patients with locally advanced non metastatic pancreatic cancer by increasing the resectability without significant acute toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962829.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Kellum A, Jagiello-Gruszfeld A, Bondarenko I, Rafi R, Giangiulio P, Messam C, Mostafa Kamel Y: Hepatobiliary (HB) safety of eltrombopag administered after carboplatin+paclitaxel (Carb+Pac) in patients (pts) with solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e20667
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since eltrombopag is excreted primarily through the liver and liver function is an important safety parameter, HB lab values and AEs were analyzed in a double-blind, placebo (pbo)-controlled, multicenter ph II study.
  • At baseline, one pt reported liver metastases (75mg group).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961706.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Quispe IR Sr, Ramos FJ, Bilbao I, Macarulla T, Cedres S, Charco R, Lázaro J, Moreiras M, Moreiras M, Tabernero J: Long-term overall survival (os) and prognostic factors of patients (pts) with surgery of liver metastases from colorectal cancer origin (lm/crc): Retrospective analysis of a Spanish single institution. J Clin Oncol; 2009 May 20;27(15_suppl):e15052
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term overall survival (os) and prognostic factors of patients (pts) with surgery of liver metastases from colorectal cancer origin (lm/crc): Retrospective analysis of a Spanish single institution.
  • Long-term survival following liver resection (LR) has improved.
  • Multiple potential prognostic factors for survival were analyzed: synchronic vs. metachronic, post-op chemotherapy (CT) vs. no, lymph node (LN) status of primary tumor, R<sub>0</sub> vs. R<sub>1-2</sub> resection, gender, location of primary tumor, number and size of metastases, and unilobar vs. bilobar disease.
  • Pts' characteristics: 123 male, 67 female; median age 63 yrs (32-85); 95 pts synchronic, 95 metachronic; 145 pts (76%) received post-op CT; LN status was <sub>p</sub>N<sub>0</sub> in 61 (32%) pts, <sub>p</sub>N<sub>1</sub> in 74 (39%) and <sub>p</sub>N<sub>2</sub> in 52 (27%).
  • 5-year OS differed between metachronic and synchronic (64% vs. 39%; p<0.001); LN-status (73% for <sub>p</sub>N<sub>0</sub> vs. 41% for <sub>p</sub>N<sub>1-2;</sub> p<0.001); R<sub>0</sub>/R<sub>1-2</sub> surgery (58% for R<sub>0</sub> vs. 21% for R<sub>1- 2</sub>; p=0.002).
  • Non-significant factors for prognosis were gender, location of primary tumor, number and size of metastases, bilobar disease and adjuvant CT.
  • CONCLUSIONS: Pts with LM/CRC who undergo liver resection can achieve long-term OS, our data identifying as prognostic factors: LN status, synchronic/metachronic disease and Type of resection (R<sub>0</sub>).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964539.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fine R, Moorer G, Sherman W, Chu K, Maurer M, Chabot J, Postolov I, Prowda J, Schreibman S, Levitz J: Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4623
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of GTX chemotherapy in metastatic pancreatic cancer.
  • This GTX regimen was designed to inhibit MEK-ERK phosphorylation and increase BAX and BAK and also decrease BCL-2 in pancreatic cancer cell lines.
  • Based on these findings, we pursued a prospective clinical trial evaluating the activity of GTX in previously untreated patients with metastatic pancreatic cancer.
  • METHODS: Patients with histologically confirmed metastatic adenocarcinoma of the pancreas, median age 60, 63% male, ECOG PS 0-2, received capecitabine 1500mg/m2/day total orally in divided doses, days 1 thru 14, gemcitabine 750mg/m2 IV over 75 minutes followed by docetaxel 30mg/m2 IV on days 4 and 11 on a 21 day cycle.
  • Scans were completed every 9 to 10 weeks to assess for tumor response by RECIST criteria.
  • Secondary endpoints were overall survival (OS) measured as time from start of GTX to death, time to treatment failure (TTF) measured as time from start of GTX to disease progression or other reason for a halt in therapy.
  • 35 patients (85%) had liver metastases.
  • CONCLUSIONS: The combination of gemcitabine, docetaxel, and capecitabine has activity in metastatic pancreatic cancer with a median survival over 1 year.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964215.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Wicherts DA, de Haas RJ, Sebagh M, Ciacio O, Lévi F, Paule B, Azoulay D, Bismuth H, Castaing D, Adam R: Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: Impact on outcome of liver surgery for colorectal metastases. J Clin Oncol; 2009 May 20;27(15_suppl):4097
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: Impact on outcome of liver surgery for colorectal metastases.
  • : 4097 Background: Regenerative nodular hyperplasia (RNH) represents the worst evolutive stage of vascular lesions induced by prolonged chemotherapy on the liver.
  • Its incidence and impact on the outcome of resection for colorectal liver metastases (CLM) are however unknown.
  • Detailed histopathologic analysis of the nontumoral liver was performed at first and repeat hepatectomies according to a standard format.
  • The presence of RNH was associated with increased postoperative hepatic morbidity (23% vs 11%) (P=0.05).
  • RNH disappeared at second hepatectomy in both patients following prolonged treatment with irinotecan.
  • CONCLUSIONS: Patients with CLM that receive prolonged courses of preoperative oxaliplatin have an increased risk of RNH and associated postoperative hepatic morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960752.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Lu Q, Zhao A, Shen L: Preoperative transcatheter arterial chemoembolization (TACE) and chemotherapy for hepatic colorectal metastases: Impact on hepatic histology and postoperative outcome. J Clin Oncol; 2009 May 20;27(15_suppl):e15090
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative transcatheter arterial chemoembolization (TACE) and chemotherapy for hepatic colorectal metastases: Impact on hepatic histology and postoperative outcome.
  • : e15090 Background: The objective was to evaluate the effect of preoperative administration of TACE and chemotherapy on hepatic injury and on postoperative outcome in patients with colorectal liver metastases (CRM) Methods: Seventy seven patients underwent hepatic resection for CRM between January 1999 and December 2007 were evaluated.
  • Pathologic review of the non-tumorous liver was performed using established criteria for steatosis, steatohepatitis, and sinusoidal dilation.
  • CONCLUSIONS: Preoperative TACE treatment may cause pathological liver injury, and increase postoperative morbility after hepatic surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964609.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Pineda C, Cadogan KV, Cadogan MA: Distribution of metastases in NSCLC: Economic impact of imaging. J Clin Oncol; 2009 May 20;27(15_suppl):e19036
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of metastases in NSCLC: Economic impact of imaging.
  • Given that many patients have metastases to several organs, one important question is - "what is the frequency of metastases in the chest, the abdomen, the pelvis, elsewhere?
  • RESULTS: We found that there were 690 metastases to the chest, 205 to the abdomen, 80 to the bones, 18 to the pelvis, 13 to the brain and 23 others, not specified.
  • If we consider the actual incidence of metastases, we find the following absolute statistics: 16 patients had pelvic involvement.
  • This compares with 42 patients with adrenal metastases, 81 with liver metastases, 80 with bone metastases, 112 with hilar adenopathy, and 159 with mediastinal adenopathy. (See Table ) Conclusions: The cost of a CT of the pelvis varies, but is estimated at approximately $2000[Fred, Herbert L., MD, MACP.
  • SEER Cancer Statistics Review, 1975-2005.
  • National Cancer Institute. 03JAN2009. http://seer.cancer.gov/csr/1975_2005/ .].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Adam R, Wicherts DA, de Haas RJ, Lévi F, Paule B, Azoulay D, Castaing D: Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab. J Clin Oncol; 2009 May 20;27(15_suppl):4093
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab.
  • : 4093 Background: The influence of bevacizumab on postoperative morbidity in patients with colorectal liver metastases (CLM) submitted to hepatectomy has been evaluated.
  • However, in spite of a potential inhibition of liver regeneration, its impact on postoperative liver function recovery remains unknown.
  • Postoperative evolution of liver function variables was compared with that of 70 bevacizumab-naïve patients.
  • Baseline liver function tests as well as postoperative liver function recovery were similar between patients treated with or without bevacizumab (Table).
  • CONCLUSIONS: Preoperative bevacizumab treatment has no impact on short-term liver function recovery after hepatic resection for CLM and has no deleterious effect on the incidence of postoperative morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961669.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Vigo SA, Sansano M, Marmissolle F, Mainella A, Lujan L, Price P, Antonelli M, Mohamed F, Giacomi N: Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11634
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer.
  • : e11634 Background: Breast cancer (BC) rarely occurs in young women.
  • It is believed that tumor is more aggressive in biologic nature in this group of pts.
  • OBJECTIVE: to describe Her2/neu status, tumor behavior and prognosis in women aged 35 and under with BC.
  • METHODS: We reviewed the records of 45 women aged 35 years or less, with diagnosis of BC between 1999 and 2007.
  • Stage at diagnosis was I 2 pts and II 6 pts.
  • 5 out of the 8 pts with Her2/neu tumors had axillary node involvement (11.1% out of the total of population), and tumor size was more than 2cm at diagnosis.
  • Disease free survival of 24 month was achieved in 5pts, 1pt died with bone, lung and liver metastases.
  • 2pts had progressive disease (bone and lung metastases one of them, and local recurrence the other one).
  • In this small group of pts lymph node involvement was frequent and tumor size was more than 2cm.
  • Progressive disease with distant metastases in bone, lung and liver was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Levine MN, Deitchman D, Julian J, Liebman H, Escalante C, O'Brien MC, Ramirez L, Weise-Kelly L, Solymoss S: A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20514
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer.
  • : e20514 Background: Cancer patients receiving chemotherapy, biologic, and molecular targeted therapies are at increased risk of venous thromboembolism (VTE).
  • We wanted to assess the feasibility of A in cancer.
  • METHODS: In a randomized phase II trial, patients with metastatic cancer on 1<sup>st</sup> or 2<sup>nd</sup> line chemotherapy received study drug once daily for 12 weeks; either 5, 10 or 20 mg of A, or placebo.
  • 23% had liver metastases.
  • The numbers of patients with events were: Conclusions: Apixiban was well tolerated in patients with advanced cancer on chemotherapy.
  • These results support further study of A in phase III trials for VTE prevention in cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960918.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Osako T, Nishimura R, Okumura Y, Hayashi M: Current status of treatment of local recurrence and distant metastasis of triple negative breast cancer in Japanese population. J Clin Oncol; 2009 May 20;27(15_suppl):e11548
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of treatment of local recurrence and distant metastasis of triple negative breast cancer in Japanese population.
  • : e11548 Background: Triple-negative breast cancers have an aggressive clinical history such as high incidence of visceral metastases, high rate of cerebral metastases, high rate of local recurrence, and early age of onset.
  • METHODS: From the medical records of our hospital, we retrospectively reviewed breast cancer patients whose three markers were available and describe the relationship between current therapy and clinical outcome.
  • RESULTS: Between 1998 and 2007, 1967 breast cancer patients were treated in Kumamoto City Hospital.
  • As of December 2008, with a median follow-up time of 31months, 53 patients (20.0%) with TNBC had locoregional recurrences or distant metastases (17 local recurrences, 15 nodal recurrences, 44 distant metastases).
  • Of 53 patients with recurrences, 31 had initial locoregional recurrence and 19 had initial distant metastases.
  • Forty two patients had already been dead and common causes of death were lung metastases (19 patients), liver metastases (11 patients), and brain metastases (8 patients).
  • Furthermore, patients with initial distant metastases had significantly poorer survival than those with initial locoregional recurrence (p=0.015).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964664.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Aprile G, Miscoria M, Baldin P, Casetta A, Pandolfi M, Di Loreto C, Pizzolitto S, Pizzolitto S, Foltran L, Fasola G, Puglisi F: Chemotherapy-induced thymidine phosphorylase modulation in colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15050
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced thymidine phosphorylase modulation in colorectal cancer.
  • Preliminary evidence suggests that TP immunohistochemical expression may predict benefit from first-line treatment of metastatic colorectal cancer (CRC) with C plus irinotecan.
  • The aim of the present analysis was to verify if TP expression differs among primary and paired metastases in CRC patients, or may vary depending on patients' exposure to chemotherapy.
  • METHODS: TP expression was evaluated by immunohistochemistry (clone p-P-GF.44C, Abcam, Cambridge, UK) in a series of 120 primary CRC and their matched distant metastases.
  • Sites of biopsied metastases were liver (n=41), lung (n=10), and peritoneum (n=6).
  • Metastases were asynchronous in 42% of patients.
  • Higher TP expression was observed in primary cancers than in metastases (36.8% vs. 15.8%, p=0.007).
  • Among patients who received at least one cycle of chemotherapy before metastasis sampling (38.6%), a TP expression decrease was demonstrated in only 13% of metastatic samples.
  • Oppositely, a significantly higher proportion of untreated patients lost TP expression in metastasis sites (36%, p=0.01).
  • CONCLUSIONS: In advanced CRC patients, TP expression tend to decrease in metastases, particularly in those patients who did not receive chemotherapy before metastatic sampling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964542.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Allegro SM, Rowsell C, Law C, Ko Y: Histological hepatic changes in patients undergoing liver resection for colorectal metastasis: A retrospective cohort study. J Clin Oncol; 2009 May 20;27(15_suppl):e15034
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological hepatic changes in patients undergoing liver resection for colorectal metastasis: A retrospective cohort study.
  • : e15034 Background: Patients with colorectal cancer (CRC) with liver metastases (LM) have a poor prognosis and the only potential cure is surgical resection.
  • However, chemotherapy can be associated with hepatic toxicity which may influence postoperative morbidity.
  • 53 (53%) patients had positive lymph nodes (primary tumor) and 51 (48%) had with synchronous LM.
  • Pathological analysis of the resected liver segments reviewed mild (<30%) steatosis in 58% of patients.
  • There were no significant increased rates of liver toxicity in patients with NC.
  • CONCLUSIONS: This study demonstrates that neoadjuvant chemotherapy, although associated with increased steatosis is not associated with increased perioperative morbidity and mortality with liver resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964495.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Bensalem A, Bouzid K: Docetaxel plus capecitabine in the treatment of previous anthracycline-treated patients with metastatic breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e12014
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel plus capecitabine in the treatment of previous anthracycline-treated patients with metastatic breast cancer.
  • : e12014 Background: Anthracyclines have been considered the challenge of the treatment of metastatic breast cancer.
  • We conducted a study in previously anthracyclines treated metastatic breast cancer by the regimen docetaxel 75 mg/m2 Day 1 - capecitabine 2500 mg/m2 day split-up over 2 daily doses from Day 1 to Day 14; every 21 Days.
  • METHODS: Patients were eligible if they had metastatic breast cancer after an adjuvant setting by anthracyclines.
  • 100 % of patients had metastatic breast cancer.
  • The sites of metastases were liver in 14 ( 77.7%), lung in 5 (27.7%) and bone in 9 (50%).
  • 11 patients (61.1%) had 1 or 2 metastatic sites, 7 (38.9%) had 3 metastatic sites.
  • The main toxicities were as follows: neutropenia grade 3 in 3 patients (16.6 %), anemia grade 2-3 in 2 patients (11.1%), fatigue in 2 patients (11.1%), hand-foot syndrome in 7 patients (38.9%), vomiting-nausea in 4 patients (22.2%), diarrhea in 2 patients (11.1%), liver toxicity in 3 patients (16.6%).
  • CONCLUSIONS: In this preliminary analysis, the combination of docetaxel - capecitabine in the treatment of previously anthracyclines treated metastatic breast cancer appears to be an active schedule.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964240.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Harrop R, Shingler WH, Goonewardena M, de Belin J, Kelleher M, Drury N, Treasure P, Naylor S: Analysis of immunological and clinical data resulting from four phase I and II trials of MVA-5T4 in colorectal cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):3058
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of immunological and clinical data resulting from four phase I and II trials of MVA-5T4 in colorectal cancer patients.
  • : 3058 Background: The attenuated vaccinia virus MVA has been engineered to deliver the tumor antigen 5T4 (MVA-5T4; TroVax).
  • MVA-5T4 has been tested in one phase I/II and three phase II clinical trials in colorectal cancer patients.
  • METHODS: Patients with histologically proven CRC were recruited to 4 independent trials in which 3 to 6 vaccinations of MVA-5T4 were scheduled to be administered either as a monotherapy, as adjuvant/neoadjuvant to surgery for respectable liver metastases or alongside treatment with FOLFIRI or FOLFOX.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Van Den Eynde M, Hendlisz A, Peeters M, Defreyne L, Maleux G, Vannoote J, Delatte P, Paesmans M, Van Laethem J, Flamen P: Prospective randomized study comparing hepatic intra-arterial injection of Yttrium-90 resin-microspheres (HAI-Y90) with protracted IV 5FU (5FU CI) versus 5FU CI alone for patients with liver-limited metastatic colorectal cancer (LMCRC) refractory to standard chemotherapy (CT). J Clin Oncol; 2009 May 20;27(15_suppl):4096
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective randomized study comparing hepatic intra-arterial injection of Yttrium-90 resin-microspheres (HAI-Y90) with protracted IV 5FU (5FU CI) versus 5FU CI alone for patients with liver-limited metastatic colorectal cancer (LMCRC) refractory to standard chemotherapy (CT).
  • We hypothesized a significant improvement of the patient's outcome after internal radiotherapy of the hepatic metastases with HAI-Y90 given along with 5FU CI over 5FU CI alone.
  • Primary endpoint was time to liver progression (TTLP).
  • Secondary endpoints were time to progression (TTP), overall survival (OS) and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961667.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Rugo HS, Campone M, Amadori D, Wardley A, Villa E, Conte PF, Mudenda B, McHenry B, Pivot X: Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):1029
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC).
  • Ixa/bev has greater preclinical activity than pac/bev in human tumor models.
  • The primary objective of this trial was to evaluate objective response rates (ORR) of ixa/bev given weekly or every 3 weeks relative to pac/bev as 1st line therapy for women with advanced breast cancer.
  • METHODS: Women with measurable disease and no prior chemotherapy for advanced breast cancer (locally advanced or MBC) were randomized in a 3:3:2 ratio to Arm A (ixa 16 mg/m<sup>2</sup> IV on days 1, 8 & 15 q28 days/ bev 10 mg/kg IV q 2 wks), Arm B (ixa 40 mg/m<sup>2</sup> IV q3 wks / bev 15 mg/kg IV q 3 wks) or Arm C (pac 90 mg/m<sup>2</sup> IV, schedule/bev as in Arm A).
  • Baseline characteristics were balanced between arms except for liver metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961032.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Garufi C, Torsello A, Tumolo S, Mottolese M, Campanella C, Zeuli M, Lo Re G, Sperduti I, Pizzi G, Ettorre GM: POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J Clin Oncol; 2009 May 20;27(15_suppl):e15020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM).
  • Aim of the study was to have at least 30% liver resection rate (power of 80% for p0=10% and p1=25%).
  • Primary tumor: colon/rectum 34/9, primary tumor resected 39 pts (79%), synchronous metastases: 35 pts (81%), liver <25%/25%: 9/34 ((21/79%); median CEA/CA19-9: 55 ng/ml (1-6,600)/91.8 U/L (2.66440); unresectability: (a): 9 (21%), (b):14 (33%), (c) 1, (d): 4 (9%), (e): 15 (35%).
  • Median number (n.) of courses (c) was 10 (2-18), median n. of c before surgery (s) was 5 (3-10) and after s was 6 (1-6); median time from last c to s was 2 wks (2-4), from s to recovery chemo was 10 wks (2-16).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964412.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. El Cheikh J, Goncalves A, Esterni B, Furst S, Faucher C, Chabannon C, Gravis G, Extra J, Viens P, Blaise D: Allogeneic stem cell immunotherapy for advanced metastatic breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e12012
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell immunotherapy for advanced metastatic breast cancer.
  • : e12012 Background: Despite continuous progress, advanced breast cancer (ABC) remains an incurable disease.
  • Immunotherapy using allogeneic stem cell transplantation (ASCT) has been proven successful in malignant hematological diseases.
  • We have investigated ASCT as a possible way of improving tumor control in ABC.
  • RESULTS: Pre-treatment characteristics of pts receiving ASCT were the following: ER or PR +, 79%; HER-2+, 27%; liver metastasis, 48%; adjuvant chemotherapy, 90%; median number of metastatic sites, 2 (1-4); 95% have received anthracyclines and/or taxanes; 71% have received endocrine therapy; 48% received more than 2 lines of cytotoxics; median age at transplant was 39 years (range 22-57).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964242.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Kersten S, Wein A, Albrecht H, Reulbach U, Maennlein G, Wolff K, Ostermeier N, Hohenberger W, Hahn EG, Boxberger F: Palliative systemic chemotherapy with gemcitabine (GEM) and 5-fluorouracil (5-FU) as 24h-infusion in patients with advanced inoperable biliary tract cancer (UICC stage IV). J Clin Oncol; 2009 May 20;27(15_suppl):e15633
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative systemic chemotherapy with gemcitabine (GEM) and 5-fluorouracil (5-FU) as 24h-infusion in patients with advanced inoperable biliary tract cancer (UICC stage IV).
  • : e15633 Background: Due to the late diagnosis of biliary tract carcinomas in an advanced tumor stage, the application of palliative chemotherapy frequently remains as a possible treatment option.
  • The aim of this study is to evaluate the efficacy and toxic side effects of a chemotherapy schedule consisting of GEM combined with 5-FU in patients (pts.) with metastatic biliary tract cancer.
  • METHODS: Evaluation of 35 pts. based on our prospective tumor registry data; essential inclusion criteria: histologically proven adeno-carcinoma, UICC stage IV, chemonaivity; all the pts. were presented in the interdisciplinary tumorboard of Erlangen University and were primarily non-curatively-resectable (n = 35); evaluation period: 11/1998 - 09/2008; treatment schedule: 1.000 mg/m<sup>2</sup> of GEM as a 0.5h-infusion (inf.) combined with 2.000 mg/m<sup>2</sup> of 5-FU as a 24h-inf. via port catheter on day 1, 8, 15 qd 22.
  • RESULTS: Median age: 64 years; men/women: n=18/17; ECOG 0/1/2: n=10/21/4; localisation: intrahepatic bile ducts: n=19, extrahepatic bile ducts: n=11; gall bladder: n=4; metastases: liver: 91.4%, lymph nodes: 51.4%, peritoneum: 28.8%, bones: 8.6%, intestine: 8.6%, skin: 2.9%, lungs: 2.9%; chemotherapy applications: total number: 486, average value/patient: 13.9; CA 19-9 elevated yes/no: n=13/22 (37.1%/62.9%); CEA elevated yes/no: n=15/9 (42.9%/25.7%, not evaluable: 11); higher grade toxicity (III or IV): leukocytopenia III: 14.3%, thrombocytopenia III: 2.9%, weariness III: 2.9%, diarrhea III: 5.7%, diarrhea IV: 2.9%, vomiting IV: 2.9%, pain III: 5.7%, ascites III: 5.7%, infections III: 2.9%, thromboembolia IV: 2.9%, elevated bilirubin value III: 1.7%, grade IV: 8.3%; deep leg vein thrombosis: 15%; median TTP: 5.1 months (95% CI: 2.9 - 7.2); median overall survival: 10.4 months (95% CI: 7.9 - 12.9); 6-months-/1-year-/2-year-survival rate: 65.7%/45.7%/17.1%; response rate: PR: n=5 (14.3%), SD: n=18 (51.4%), PD: n=7 (20%), not evaluable: n=5 (14.3%); tumor control (PR/SD): n=23 (65.7%); median follow-up: 10.4 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962748.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Zeldis JB, Heller C, Seidel G, Yuldasheva N, Stirling D, Shutack Y, Libutti SK: A randomized phase II trial comparing two doses of lenalidomide for the treatment of stage IV ocular melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):e20012
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20012 Background: Ocular melanoma is the most common primary intraocular malignancy in adults with an incidence of 4.3 new cases per million.
  • Approximately 50% of patients will develop metastases and the mean survival of those with liver metastases is 8-10 months.
  • METHODS: Patients with stage IV ocular melanoma, who met eligibility criteria and demonstrated disease progression, were enrolled on an IRB approved prospective random assignment trial comparing 5 mg and 25 mg of lenalidomide administered once a day orally for 21 days with a 7 day recovery (one cycle).
  • RESULTS: Seventeen patients (13 female, 4 male; mean age 53) met eligibility criteria and were randomized to 5 mg (9 patients) or 25 mg (8 patients) of lenalidomide.
  • Based on these results, further development of lenalidomide in combination with other agents should be considered for the treatment of metastatic ocular melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962565.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Bedikian AY, Sato T, Kim KB, Papadopoulos NE, Hwu W, Homsi J, Davies M, Cheung C, Imperiale SM, Prasad P, Hwu P: Phase II study of vincristine sulfate liposomes injection in patients with metastatic uveal melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9067
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of vincristine sulfate liposomes injection in patients with metastatic uveal melanoma.
  • : 9067 Background: Preclinical and clinical studies showed that liposomal encapsulation of vincristine sulfate (VCR) results in increased drug circulation time and accumulation of VCR at the tumor site.
  • Of the 27 previously treated patients with metastatic melanoma in the Marqibo pharmacokinetic studies, 3 patients had a tumor response, including one patient with uveal melanoma metastatic to the lung that experienced a complete response.
  • METHODS: Patients with metastatic uveal melanoma with no more than one prior systemic therapy were enrolled.
  • Patients with controlled brain metastases were allowed.
  • Marqibo (2.25 mg/m2 by 1-hour intravenous infusion, no dose capping) was administered every 14 days until tumor progression.
  • Median age was 65 years (range 38-79), 23% were previously treated with systemic chemotherapy, 86% had liver metastasis and 96% had M1c disease.
  • Twenty-one patients were evaluable for response; one patient discontinued the treatment after a single dose of therapy for toxicity without tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962153.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Santomaggio A, Ricevuto E, Cannita K, Bruera G, Tudini M, Lanfiuti Baldi P, Mancini M, Porzio G, Marchetti P, Ficorella C: "Poker" schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4125
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Poker" schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study.
  • Thus we evaluated in a phase II study the addition of BEV to the triplet combination CPT-11/OHP/5-fluorouracil (5-FU) as first line chemotherapy in metastatic colorectal carcinoma (MCC).
  • METHODS: Main inclusion criteria: histologically diagnosis of colorectal cancer (CRC) with measurable disease; age 18-75 yrs; adequate bone marrow reserve and renal and hepatic function; no cardiac diseases; no uncontrolled hypertension; no thromboembolic diseases or coagulopathy, no preexisting bleeding diatheses.
  • Secondary endpoints: time to progression (TTP), overall survival (OS), toxicity and quality of life.
  • 17 pts (35%) had only liver metastasis and R0 resection was performed in 3 pts (18%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961244.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Tommasi S, Silvestris N, Petriella D, Pinto R, Pilato B, Lacalamita R, Gernone A, Paradiso A, Zito FA, Colucci G: Epigenetic alterations of primary tumor and metastatic site of colorectal carcinoma (mCRC). J Clin Oncol; 2009 May 20;27(15_suppl):4128
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic alterations of primary tumor and metastatic site of colorectal carcinoma (mCRC).
  • Aberrant DNA promoter methylation frequently occurs as early event in carcinogenesis as important mechanism of inactivation of tumor suppressor genes.
  • Our hypothesis states a potential role of tumor suppressor methylation in inhibiting EGFR signaling cascade thus blocking anti-EGFR therapeutic effect.
  • Our further aim was to evidence the role of epigenetic alterations in metastatic progression.
  • Primary tumor and liver metastatic tissues have been characterized for k-ras and BRAF mutations and for promoter methylation of p16, RASSF1A and RARbeta suppressor genes by Quantitative Methylation-Specific PCR (QMSP).
  • The two genes conserved their characteristics in both site of disease: primary tumor and liver metastasis.
  • RARbeta promoter methylation mean content resulted significantly higher in k-ras mutated with respect to k-ras wt tumors (209.96 vs 0.44 respectively, p<0.01).
  • Interestingly, the percentage of RARbeta methylation in metastatic sites of k-ras wt tumors is significantly higher than that of the related primary tumors (20% vs 100% respectively, p<0.05).
  • RASSF1A and p16 genes resulted less methylated in k-ras wt patients and significantly higher methylated in metastatic than in primary site (p<0.01).
  • CONCLUSIONS: These results might suggest that genetic and epigenetic changes specifically interact to promote tumorigenesis of colon carcinoma and that epigenetic events have to be taken into account when setting biological therapy mainly in metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961239.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Gomez HL, Philco M, Castaneda C, Pimentel P, Escandon R, Seroogy J, Saikali K, Wolff A, Conlan M: A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence. J Clin Oncol; 2009 May 20;27(15_suppl):1077
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II trial of ispinesib, a kinesin spindle protein (KSP) inhibitor, dosed q14d in patients with advanced breast cancer previously untreated with chemotherapy for metastatic disease or recurrence.
  • In a phase II trial of ispinesib dosed at 18 mg/m<sup>2</sup> q21d in patients (pts) with advanced breast cancer after anthracycline and taxane failure, the response rate was 4/45 (9%).
  • Eligibility criteria: advanced breast cancer; no prior chemotherapy (CT) except neoadjuvant or adjuvant and ≥ 1 yr elapsed since CT; no CNS metastases; ECOG 0-1.
  • 9 pts were stage IV; 11 were chemo-naïve; 5 had prior anthracycline and/or taxane; 4 were HER-2+ and 5 ER-, PR-, HER-2-.
  • At the 14 mg/m<sup>2</sup> dose level, 2/7 pts had DLTs of transient grade 3 AST and ALT increases after cy 1 d15 dosing; both without increases upon retreatment; 1 in a pt with liver metastases; neither pt had significant increases in alkaline phosphatase or bilirubin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Yu B, Zhang M, Wu W, Chen L, Peng L, Bian G, Fu J, Fei C: Neoadjuvant chemoradiotherapy for locally advanced low-lying rectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15095
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiotherapy for locally advanced low-lying rectal cancer.
  • : e15095 Objective: The aim of this trial was to explore the possibility of further improvement of efficacy in neoadjuvant chemoradiation for the treatment of locally advanced low-lying rectal cancer and the management of patients with clinical complete regression.
  • METHODS: 192 cases with locally advanced low-lying rectal cancer (T3/T4 or N+) received preoperative radiotherapy comprising 40-46 Gy/20-23 fractions and concomitant oral capecitabine 625 mg/m<sup>2</sup> bid for 10 weeks prior to surgery.
  • 17 pts (8.9%) had clinical complete tumor regression without surgery, 175 pts underwent curative resection including of 134 pts with low anterior resection (LAR), 32 pts with ultra-low anterior resection with Parks' coloanal anastomosis and among them 6 pts with diverting temporary colostomy and 9 pts with APR.
  • According to the pathological staging: T<sub>0</sub>N<sub>0</sub> 41 cases, T<sub>2</sub>N<sub>0</sub> 43 cases, T<sub>3</sub>N<sub>0</sub> 77 cases, T<sub>4</sub>N<sub>0</sub> 5 cases, T<sub>2</sub>N<sub>1</sub> 11 cases, T<sub>3</sub>N<sub>1</sub> 13 cases, T<sub>4</sub>N<sub>0</sub> 5 cases, and T<sub>4</sub>N<sub>1</sub> 2 cases; in semiquantitative Dworak's tumor regression grade, TRG0 8 pts,TRG1 32, TRG2 28,TRG3 83 and TRG4 41 with an overall tumor downstaging of 79.2%.
  • During the time, 11 pts had lung metastases, 6 liver metastases and 7 had local recurrences.
  • CONCLUSIONS: Neoadjuvant chemoradiotherapy has high efficacy resulting in tumor down-staging, increased resectability and sphincter preservation, and a reduction in local recurrences.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964612.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Vieitez J, Jiménez Fonseca P, Fernandez de Sanmamed M, Pitiot AS, Crespo G, Berros J, Muriel C, Izquierdo M, Pardo P, Lacave A: Incidence and significance of K-RAS mutation in first line treatment of colorectal cancer (cc): Experience of a single institution (Hospital Universitario Central de Asturias (HUCA)). J Clin Oncol; 2009 May 20;27(15_suppl):e15081
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and significance of K-RAS mutation in first line treatment of colorectal cancer (cc): Experience of a single institution (Hospital Universitario Central de Asturias (HUCA)).
  • : e15081 Background: Although the significance of K-RAS mutation and cetuximab/panitumumab has been established in first line (ASCO 08 abstract 2# and 4000#) and in previously treated patients (pts) (NEJM 2008; 359: 1757.
  • METHODS: Sample tissue of alive patients diagnosed of stage IV colorectal cancer were analyzed for the presence of K-RAS mutation by PCR amplification and direct sequencing.
  • Data regarding presence of K-RAS mutation were retrospectively analyzed in relation to clinical data.
  • 25 pts had received previous complementary treatment; in 80 pts primary tumor was previously resected (85%); median number of affected organs was 1 (1-4); in first line 76 pts received bevacizumab and 18 did not received any biological agent.
  • Multivariable Cox analysis did not find any significant difference between sex (p=0.78), primary resected organ (p=0.28), liver metastases (p=0.37), LDH value at diagnosis (p=0.0.43), employ of biological agents in first line (p=0.37) or mutation in K-RAS gene (p=0.68).
  • CONCLUSIONS: The percentage of K-RAS mutants is coherent with the results of the literature; mutations Gly12Asp, Gly12Val, and Gly13Asp represents the majority of the cases (81%); no significant relation was found between responses or DFS and mutations in the gene.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964548.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Vaklavas C, Tsimberidou AM, Moulder S, Ng C, Naing A, Daring S, Bedikian A, Uehara C, Kurzrock R: A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement. J Clin Oncol; 2009 May 20;27(15_suppl):e13512
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement.
  • : e13512 Background: Patients with liver metastases treated on phase I clinical trials have a median survival of 7.5 months (range, 6.0-9.5).
  • We conducted a phase I study of hepatic arterial infusion (HAI) and intravenous (IV) chemotherapy in patients with advanced cancer and dominant liver involvement.
  • Diagnoses were breast cancer (n=11), colorectal cancer (n= 8), ocular melanoma (n=4), and other (n=7).
  • Treatment resulted in a partial response (PR)(n=4) or stable disease (SD)(n=6) by RECIST in 10 (48%) patients and lasted for ≥4 months (tumor reduction by 5% to 44%).
  • Four (19%) patients achieved a PR (tumor reduction by 38%, 42%, 44% and 51%, for 4, 4, 6, and 4 months, respectively).
  • Of the 11 patients with breast cancer, 3 had a PR and 4 had SD.
  • Of 4 patients with ocular melanoma, 1 had a PR and 1 SD.
  • Of 11 evaluable patients treated at the MTD, 3 (27%) had a PR and 4 (36%) had SD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961306.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Lee KS, Ro J, Park IH, Kim EA, Nam B: Phase II study of irinotecan plus capecitabine in patients with anthracycline and taxane pretreated metastatic breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):1093
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan plus capecitabine in patients with anthracycline and taxane pretreated metastatic breast cancer.
  • : 1093 Background: Irinotecan (I) and capecitabine (X) have demonstrated single agent activity against breast cancer by different antitumor mechanism without cross-resistance.
  • To assess the objective response rate (RR) of IX combination in metastatic breast cancer (MBC) patients (pts) was the primary end point.
  • Among 35 evaluable pts excluding 1-consent withdrawal, 86% received at least one prior chemotherapy for MBC; 20% had stage IV disease with 66% lung/37% liver metastases; 80% had PS 0-1; 77% had hormone receptor (HR) positive tumors, 20% triple negative disease and 3% HER-2 positive tumors.
  • Overall RR was 60% (95% CI, 43.5-74.5) with median response duration of 6.3 months (range, 1.0+-17.1+); 2 CR (6%), 19 PR (54%), 8 SD (23%), and 6 PD (17%) with similar RR between HR+ (63%) versus triple negative disease (57%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961236.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Tomao S Sr, Spinelli G, Rossi L, Pasciuti G, Arcangeli G, D'Aprile M, Veltri E, Baiano G: Safety, efficacy, and time to clinical response with bevacizumab plus FOLFIRI regimen in metastatic colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15138
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety, efficacy, and time to clinical response with bevacizumab plus FOLFIRI regimen in metastatic colorectal cancer.
  • : e15138 Background: Bevacizumab (BEV) has shown clinical activity in metastatic colorectal cancer patients (mCRC)and randomised phase III trials have demonstrated that this agent significantly improves overall and/or progression-free survival when added to first-line irinotecan based chemotherapy (CT) regimens.
  • We evaluated the efficacy and safety of BEV plus FOLFIRI (irinotecan, 5- fluorouracil, and leucovorin) as first line treatment in 27 consecutive metastatic colorectal cancer cases, with the primary end point to calculate the median time to clinical response with this chemotherapeutic schedule.
  • Elegibility criteria had to be: mCRC; no prior CT for metastatic disease; ECOG PS 0/1, adequate organ function; no CNS metastases.
  • The sites of metastases were: liver (15 pts), lung (5 pts), liver and lung (5 pts), peritoneal wall (2 pts).Median follow-up was 18 weeks.
  • Two patients had complete response(CR) and 13 pts partial response (PR), with an overall response rate of 57.7%.
  • We observed a median time to clinical response of 11 weeks, evaluated with tumor markers and with CT/NMR/US examinations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960895.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Takeda A: Use of anti-neuropilin 1, 2 antibodies to predict colorectal cancer prognosis. J Clin Oncol; 2009 May 20;27(15_suppl):e15111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of anti-neuropilin 1, 2 antibodies to predict colorectal cancer prognosis.
  • Neuropilins are widely expressed not only normal developing tissues but also several types of tumor cells.
  • It was reported that the expression of NRP-1 is increased by VEGF, mediated through VEGFR-2, which correlates with tumor growth and invasiveness in colorectal cancer.
  • NRP-2 knockout mice studies showed marked deficits in the development of small lymphatic vessels and its function was associated with the formation of lymphatic network, but the role of NRP-2 in colorectal cancer remains unknown.
  • In recent study, we have analyzed the expression of NRP-1 and NRP-2 in some cultured cell lines by western blot and the clinicopathological significance in colorectal cancer.
  • NRP-1 and NRP-2 gene expression was evaluated by RT- PCR, which was compared with immunohistochemical examination of colorectal cancer tissues.
  • The expression of NRP-1 showed apparent correlation with liver metastasis (p=0.027) and venous invasion (p=0.0025), while NRP-2 expression was correlated with lymph node metastasis (0.001) and lymphatic invasion (0.039) by immunohistochemical analysis.
  • CONCLUSIONS: These results suggest that NRP-1 acts as angiogenesis factor and NRP-2 acts lymphangiogenesis factor, both of them are useful predictive marker in colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960860.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Trarbach T, Schuette K, Stoehlmacher J, Goekkurt E, Guenther H, Ubbelohde U, Stroszczynski C, Ehninger G, Folprecht G: Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15025
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer.
  • : e15025 Background: Highly active chemotherapy schedules are necessary in several clinical situations, i.e. for conversional chemotherapy in order to resect liver metastases.
  • Adding oxaliplatin or cetuximab to 5-FU / FA / irinotecan was shown to increase the efficacy of chemotherapy in patients with metastatic colorectal cancer (Falcone et al, JCO 2007, Van Cutsem et al, ASCO 2008).
  • METHODS: We performed a phase I study in patients (pts) with metastatic colorectal cancer, WHO PS 0-1 who had not been pretreated for metastatic disease.
  • Patient characteristics were as follows: median age 59 (33-72) years, 16 pts WHO PS 0, 15 pts male, 10 pts rectal cancer primary, 3 pts previous adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964399.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Joka M, Pietsch K, Paulick S, Issels R, Jauch K, Mayer B: Heterogeneous expression of prognostic and predictive antigens in primary and metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22030
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneous expression of prognostic and predictive antigens in primary and metastatic gastric cancer.
  • : e22030 Background: Metastatic spread of cancer cells is a key event in tumor progression and in determining the prognosis of patients with malignant disease.
  • This study evaluated the expression of prognostic and predictive molecules in primary and metastatic gastric cancer.
  • METHODS: The clinicopathological features of 94 patients (57,4% male, 42,6% female, median age of 66,2 years) with gastric cancer were characterized using multivariate and univariate analysis.
  • Further we compared the expression profile of biomarkers, namely EPCAM, CD44s, HLA-ABC and the associated β chain, HLA-DR, ICAM-1, LFA-3 and E-Cadherin in primary gastric tumors (n=94) and their synchronous metastases (regional lymph nodes n=32, liver n=14, peritoneum n=17) using immunoperoxidase staining.
  • RESULTS: Strong HLA-ABC expression was found in both primary and metastatic tumors.
  • High expression of HLA-ABC in liver metastases significantly correlated with metastatic disease (UICC TNM stage IV, p=0,026).
  • Contrary, the detection of HLA-DR on the cancer cells correlated with the degree of the inflammatory infiltrate (CD45, p=0,019).
  • With respect to CD44s, the prognostic marker was upregulated in the metastatic tumors independently of their localisation (p=0.009) compared to the primary lesions.
  • E-cadherin and LFA-3 expression were preferentially increased in distant metastases, but not in locally advanced gastric tumors (liver: E-cadherin, p=0.001; liver and peritoneum: LFA-3, p=0.0067).
  • E-cadherin expression was upregulated in the heterotypic spheroid model coculturing primary liver cells and N87 gastric cancer cells (80% E-cadherin positive N87 cells) compared to the homotypic spheroid model consisting of N87 cells alone (40% E-cadherin positive N87 cells).
  • CONCLUSIONS: These data suggest the consideration of the metastatic protein profile for the selection of cancer patients in new molecular therapeutic strategies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963146.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Nakai Y, Isayama H, Sasaki T, Sasahira N, Hirano K, Tsujino T, Tada M, Kawabe T, Omata M: The role of S-1 in gemcitabine-refractory pancreatic cancer: A retrospective single-institution study. J Clin Oncol; 2009 May 20;27(15_suppl):e15648
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of S-1 in gemcitabine-refractory pancreatic cancer: A retrospective single-institution study.
  • : e15648 Background: S-1 was reported to be active against gemcitabine (Gem)-refractory pancreatic cancer (PaC) in Japan and was introduced in February 2005 in our institution.
  • The introduction rates of second-line chemotherapy and the causes of introduction failure were assessed.
  • There were no differences in baseline characteristics at PD for Gem between PreS-1 and PostS-1 Groups, except for metastasis to peritoneum more prevalent in PreS-1 Group (44.7% in PreS-1 Group and 23.0% in PostS-1 Group, p=0.023).
  • The introduction rate of second-line chemotherapy increased from 12.8% in PreS-1 Group to 45.9% in PostS-1 Group.
  • Second-line chemotherapy was administered in 34 pts, 29 by S-1, 4 by 5-FU-based chemoradiation, and 1 by 5-FU.
  • The causes of introduction failure of second line chemotherapy were poor PS in 64.9%, patients' refusal in 16.2%, infection in 2.7%, adverse effects of Gem in 1.4% and jaundice in 1.4%.
  • RR, PFS, and OS for second-line S-1 were 17.2%, 2.5 Mo, and 7.8 Mo, respectively.
  • The Cox hazard model revealed PreS-1 Group (HR2.42, p=0.001) in addition to male gender (HR1.83, p=0.019), poor PS (HR3.52, p<0.001), liver metastasis (HR2.36, p=0.037), elevated LDH (per 100U/L increase) (HR 1.30, p=0.046), elevated CRP (HR 1.14, p=0.023) at PD for Gem as poor prognostic factors of RS for Gem-refractory PaC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962734.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Kindler HL, Garbo L, Stephenson J, Wiezorek J, Sabin T, Hsu M, Civoli F, Richards D: A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). J Clin Oncol; 2009 May 20;27(15_suppl):4501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC).
  • : 4501 Background: AMG 655 is an investigational, fully human agonist monoclonal antibody (IgG1) that binds human death receptor 5 (DR5), activates caspases, and induces apoptosis in sensitive tumor cells.
  • We performed a multi-center phase I trial to evaluate AMG 655 + G in metastatic PC pts.
  • Secondary endpoints included toxicity, pharmacokinetics, antibody formation, objective response rate, progression-free survival (PFS), 6-month and overall survival.
  • METHODS: Eligible pts had previously untreated metastatic PC and ECOG PS 0 or 1.
  • Pt characteristics: females 61%; ECOG PS 1 69%; median age 65 (range 35-81); liver metastases 77%.
  • After one 3 or 10 mg/kg dose of AMG 655 after G, the C<sub>max</sub> and AUC of AMG 655 were similar to those in the first- in-human single-agent study (LoRusso JCO 2007; 25: abstract 3534).
  • CONCLUSIONS: AMG 655 + G is well-tolerated and may have activity in metastatic pancreatic cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962691.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Gandola L, Nantron M, Marchianò A, Pession A, Indolfi P, Di Cataldo A, Collini P, Arcamone G, Fossati Bellani F, Spreafico F: Outcome in stage IV Wilms tumor treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials. J Clin Oncol; 2009 May 20;27(15_suppl):10031
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome in stage IV Wilms tumor treated according to the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) trials.
  • : 10031 Background: Children with metastases at diagnosis for Wilms tumor (WT) still display a worse prognosis compared to localized disease.
  • Treatment strategy across these trials evolved in terms of sparing whole lung radiotherapy (RT) in case of complete disappearance of lung metastases after primary chemotherapy and a doxorubicin cumulative dose reduction from 360 mg/m<sup>2</sup> to 240 mg/m<sup>2</sup> in TW2003.
  • Adjuvant therapy included 8-month 3-drug chemotherapy for non anaplastic "local" tumor stage I to III (flank RT for stage III), or an intensified regimen for anaplastic histology, adding etoposide, carboplatinum and ifosfamide (6 patients).
  • Overall 19 tumor failure occurred (3 in anaplastic tumors): metastases progression 9, abdominal relapse 5 (combined to liver and mediastinum in 1 case each), lung 4, liver 1.
  • Overall, RFS was 86% in patients who achieved a complete metastases remission (in 2 cases by surgery) compared to 55% in patients who did not (Logrank p<.05).
  • Noteworthy the omission of lung RT in TW2003 trial for complete responders evaluated at week 6 did not jeopardize survival (85% RFS, vs 58% for those children with persistence of metastases and lung RT).
  • There was a trend toward a worse outcome for patients with at least liver metastases (n 13) compared to those with other site (4-yr RFS 49% vs 74%, p=.1).
  • CONCLUSIONS: Failure to obtain metastases complete remission, and maybe site other than lung, should be considered for chemotherapy intensification for metastatic WT.
  • The impact of metastatic tumor burden deserves further analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Maroun J, Jonker D, Cripps C, Goel R, Asmis T, Marginean H, Chiritescu G: Phase I study of the IXO regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), as first-line therapy for metastatic colorectal cancer: Final survival results. J Clin Oncol; 2009 May 20;27(15_suppl):4082
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of the IXO regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), as first-line therapy for metastatic colorectal cancer: Final survival results.
  • : 4082 Background: This study was designed to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and efficacy of the IXO regimen when used as first-line treatment for metastatic colorectal cancer (mCRC).
  • 10 (26%) pts had subsequent liver surgery with curative intent; 1 had lung resection.
  • It appears to be particularly effective in downsizing of initially unresectable colorectal cancer liver metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Keizman D, Maimon N, Ish-Shalom M, Buchbut D, Inbar M, Klein B, Bernheim J, Goldiner I, Leikin-Frenkel A, Shpigel S, Konikoff F: An animal model for chemotherapy-associated steatohepatitis (CASH) and its prevention by the oral administration of fatty acid bile acid conjugate (FABAC). J Clin Oncol; 2009 May 20;27(15_suppl):4098
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4098 Background: Preoperative chemotherapy (irinotecan and oxaliplatin), used in patients undergoing hepatic resection of colorectal liver metastases, is associated with the development of CASH.
  • This hepatic injury increases the risk of perioperative morbidity and mortality.
  • Fatty acid bile acid conjugates (FABACs) are novel synthetic lipid molecules that were shown to prevent the formation of diet induced fatty liver.
  • Their livers were homogenized and analyzed for fat content (measured as mg lipid/g liver tissue).
  • RESULTS: There were no significant differences in animal or liver weights between the groups.
  • Liver fat content, was significantly lower (P<0.0001) among the control (51.63 mg/g) and prevention (62.13 mg/g) groups versus the oxaliplatin group (95.35 mg/g).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960751.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Sasatomi T, Ogata Y: DWIBS (diffusion weighted whole body imaging with background signal suppression) scan for colorectal cancer and its evaluation: Comparison with CT or PET scans. J Clin Oncol; 2009 May 20;27(15_suppl):e15140
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DWIBS (diffusion weighted whole body imaging with background signal suppression) scan for colorectal cancer and its evaluation: Comparison with CT or PET scans.
  • : e15140 Background: The most important clinical point for the colorectal cancer patients after surgery is to find out local recurrence and distant metastasis to liver or lungs in early state.
  • Recently, DWIBS (diffusion weighted whole body imaging with background body signal suppression) scan, one of the diffusion weighted MRI imaging methods, was developed, and it has been become used for diagnosis of lung cancer and bladder cancer instead of PET scan.
  • In this report, we examined whether it was more useful method for the diagnosis of recurrence or distant metastasis of the colorectal cancer after surgery than PET/CT scan or not.
  • METHODS: All the 12 primary colorectal carcinomas were resected at the surgical division, Kumamoto Central Hospital, Fukuoka Saisekai Ohmuta Hospital and Kurume University Medical Center from 2000 to 2008. (Table 1) After surgery, 14 recurrent regions (seven liver metastasis, two lung metastasis and five local recurrence) were diagnosed by CT and MRI scans.
  • And also the seven out of 12 cases (three liver metastasis, two lung metastasis and four local recurrence) were performed by PET scan.
  • RESULTS: All the 14 metastatic and recurrent regions (seven liver metastasis, two lung metastasis and five local recurrence ) of 12 recurrent patients were performed by DWIBS, MRI and CT scans.
  • Within the seven out of 12 recurrent patients (three liver metastasis, two lung metastasis and five local recurrence), performed by PET scan, all the liver and lung metastatic regions were detected, on the other hand, three out of four local recurrent regions were diagnosed but the other one was not diagnosed by PET scan.
  • CONCLUSIONS: DWIBS is not only useful diagnostic method for local recurrence of colorectal cancer after surgery, but also less invasive method than PET scan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960889.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Muacevic A: Robotic radiosurgery of liver metastases of solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15049
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic radiosurgery of liver metastases of solid tumors.
  • : e15049 Background: The number of patients (pts) suffering from isolated liver metastases is growing.
  • We here report the therapeutic efficacy of a robotic radiosurgery device for local control of liver metastases of solid tumors.
  • METHODS: Patients with liver metastases not qualifying for surgery were treated with single session radiosurgery (24 Gy) using robotic image-guided real-time tumor tracking.
  • For inclusion into the radiosurgery treatment protocol, tumor volumes had to be smaller than 80cc.
  • Metastases (n=27) originated from: colon (12), rectum (2), pancreas (2), lung (1), bladder (2), malignant melanoma (1), stomach (1), cholangiocellular carcinoma (2), breast (1), ovary (1), appendix (1) and endometrium (1).
  • Median tumor volume was 21cc (range 2.2-79.3).
  • CONCLUSIONS: Robotic radiosurgery with image-guided real-time tumor tracking of liver metastases is a new and promising treatment approach for pts not eligible for surgical resection and might enhance the possibilities of multidisciplinary oncological treatment concepts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Helm J, Strosberg J, Henderson-Jackson E, Hafez N, Hakam A, Nasir NA, Coppola D, Malafa MP, Larry KK, Nasir A: Expression of metastasis-associated gene products and liver metastases in pancreatic endocrine tumors. J Clin Oncol; 2009 May 20;27(15_suppl):11089
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of metastasis-associated gene products and liver metastases in pancreatic endocrine tumors.
  • We recently identified a novel set of 3 metastasis-associated genes by microarray: Palladin, p21, RUNX1T1.
  • Our aim was to evaluate the potential for these markers, individually or in combination, to predict liver metastases as an indicator of adverse outcome.
  • METHODS: Palladin, p21, and RUNX1T1 immunostains were done on a tissue microarray of 39 resected primary pancreatic endocrine neoplasms, 14 of which had hepatic metastases.
  • Receiver operating characteristic (ROC) analysis was used to choose the cutpoint in Allred score (high vs low protein expression) to optimize sensitivity and specificity for predicting liver metastases.
  • RESULTS: Nearly all tumors with liver metastases showed high Palladin and p21 levels (Allred score > 3 and > 4, respectively), while protein expression was lower in the majority of non-metastatic tumors.
  • In contrast, RUNX1T1 expression was low (Allred score < 4) in most tumors with liver metastases, but higher in all except one of the non-metastatic tumors.
  • Individual test sensitivities for predicting liver metastases were 100% for high Palladin, 93% for high p21 and 85% for low RUNX1T1, while corresponding specificities were 63%, 75%, and 96%.
  • Tumors were correctly classified as being metastatic or not (predictive accuracy) by Palladin, p21, or RUNX1T1 expression in 76%, 76%, and 92% of cases, respectively.
  • If abnormal expression of even one of 3 proteins is considered a positive test (parallel testing), then sensitivity of all 3 together for predicting liver metastases was 100%, specificity 48%, and predictive accuracy 68%.
  • CONCLUSIONS:. 1) High Palladin, high p21, or low RUNX1T1 expression have good sensitivity and specificity for predicting liver metastases in pancreatic endocrine tumors.
  • 3) Differential expression of these biomarkers may predict aggressive tumor behavior that warrants more aggressive management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963181.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Geevarghese SK, Chen A, Geller DA, de Haan HA, Iagaru A, Knoll A, Nemunaitis J, Reid TR, Sze DY, Tanabe K: Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC). J Clin Oncol; 2009 May 20;27(15_suppl):4089
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC).
  • Initial Phase 2 tumor response data using the optimal biological dose (OBD) are now presented.
  • METHODS: Patients with heavily pretreated, progressing liver mCRC received 4 doses of NV1020 (1 X10<sup>8</sup> pfu) by weekly hepatic artery infusion followed by two cycles of conventional chemotherapy.
  • Best response observed with CT was 55% (1 CR, 1 PR, 10 SD) and 59% (5 PR, 8 SD) with PET.
  • Response did not correlate with initial tumor size, SUV, or CEA, with time since primary resection, pre- or post NV1020 chemotherapy type.
  • CONCLUSIONS: NV1020 stabilizes liver metastases in highly advanced mCRC and may sensitize tumors to salvage chemotherapy resulting in extended overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Sanyal AJ, Moyneur E, Barghout V: Retrospective claims database analysis of elderly compared with nonelderly patients (pts) with newly diagnosed hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):9552
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 9552 Background: HCC is the most common type of liver cancer in the US and its incidence has been rising.
  • METHODS: De-identified, individual-level healthcare claims data from a database (MarketScan MedStat) covering all US census regions for ≥18 million lives in 2002-2008 were retrospectively analyzed.
  • Pts had ≥2 claims for primary HCC (ICD9 155.0), continuous healthcare coverage, >180 days of coverage before HCC, and no prior claims for secondary liver cancer (ICD9 197.7).
  • Pts were followed longitudinally from HCC diagnosis until end of healthcare coverage or 3/31/08.
  • Risk factors in the groups were nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH, 59% for <65 vs 50% for ≥65), hepatitis C (32% vs 11%), diabetes (29% vs 40%), alcoholic cirrhosis (16% vs 7%), and hepatitis B (9% vs 3%).
  • Most noncurative treatment options were initiated sooner in pts ≥65 y than those <65 y, whereas the opposite holds for the 2 main curative treatments (transplantation and cancer removal surgery).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963601.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Xu J, Zhong Y, Niu W, Qin X, Wei Y, Ren L, Wang J, Chen J, Qian S: Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. J Clin Oncol; 2009 May 20;27(15_suppl):4090
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery.
  • : 4090 Background: To investigate whether preoperative hepatic and regional arterial chemotherapy are able to prevent liver metastasis and improve overall survival in patients receiving curative colorectal cancer resection.
  • METHODS: Patients with Stage II or Stage III colorectal cancer (CRC) were randomly assigned to receive preoperative hepatic and regional arterial chemotherapy (PHRAC group, n=256) or surgery alone (control group, n=253).
  • The primary endpoint was disease-free survival, whereas the secondary endpoints included liver metastasis-free survival and overall survival.
  • During the follow-up period (median, 42 months), the median liver metastasis time for patients with stage III CRC was significantly longer in the PHRAC group (16±3 months v.s.
  • In stage III patients, there was also significant difference between the two groups with regard to the incidence of liver metastasis (18.9% vs 27.3%, P=0.01), 5-year disease-free survival (70.2% vs 52.0%, P=0.0076), 5-year overall survival (80.3% vs 69.5%, P=0.020) and the median survival time (40.1± 4.6 months vs 36.3 ± 3.2 months, P=0.03).
  • In the PHRAC arm, the risk ratio of recurrence was 0.63 (95% CI, 0.51-0.79, P=0.0001), of death was 0.50(95% CI, 0.32-0.67; P=0.005), and of liver metastasis was 0.70 (95% CI, 0.52-0.86; p=0.01).
  • Toxicities, such as hepatic toxicity and leucocyte decreasing, were mild and could be cured with medicine.
  • CONCLUSIONS: Preoperative hepatic and regional arterial chemotherapy, in combination with surgical resection, could be able to reduce and delay the occurrence of liver metastasis and therefore improve survival rate in patients with stage III colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961672.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T: Selective internal radiation therapy (SIRT) as salvage therapy for uveal melanoma (UM) hepatic metastases. J Clin Oncol; 2009 May 20;27(15_suppl):9066
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective internal radiation therapy (SIRT) as salvage therapy for uveal melanoma (UM) hepatic metastases.
  • : 9066 Background: The liver is the first site of metastasis in >80% of patients with UM.
  • Transarterial chemoembolization (TACE) has been used to control hepatic metastases, however, patients eventually progress through or experience complications related to TACE.
  • We report our results using SIRT as salvage therapy for patients with UM liver metastases who are no longer candidates for TACE.
  • METHODS: Patients with UM liver metastases previously treated with TACE were treated with SIRT.
  • Patients were followed 1-month post-SIRT for acute toxicity then every 3 months for tumor response evaluation and for complications of delayed toxicity.
  • Best radiographic tumor response was determined by MRI using RECIST criteria.
  • RESULTS: Five men and 7 women, ages 48-81 (median 65) with UM liver metastases were treated with SIRT after tumor progression post-TACE (n=9), complications of TACE (n=1) or patient preference (n=2).
  • Pretreatment whole liver tumor burdens were as follows: <25% (n=10), 25-50% (n=1) and >50% (n=1).
  • Patients had both hepatic lobes treated on separate occasions (n=7), one lobe (n=3) or whole liver (n=2) therapy.
  • Five patients had an increase in hepatic enzymes (Grade 1-4) at 1-month follow-up.
  • Best tumor response was as follows: CR (n=0), PR (n=0), SD (n=8), PD (n=4), with a median follow-up of 7.8 months (1.0-16.0).
  • The median time to liver progression was 7.0 months (1.0- 15.5).
  • Nine of the 12 patients, including 2 patients with >25% pretreatment tumor burden, died due to progression of liver disease (n=6), extrahepatic disease (n=1) or both (n=2).
  • Further investigation is warranted to determine if SIRT should be employed as a first line therapy for patients with UM liver metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962150.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Neumann UP, Fotopoulou C, Neuhaus P, Sehouli J: Clinical outcome of resection of liver metastasis in patients with ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16545
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of resection of liver metastasis in patients with ovarian cancer.
  • : e16545 Background: Hepatic resection has become the standard treatment for resectable colorectal liver metastases.
  • However, in patients with ovarian cancer resectable liver metastases are rare and the issue is discussed controversially due to the lack of relevant published data.
  • The aim of this retrospective study was to evaluate the efficacy of hepatic resections in patients with ovarian cancer.
  • METHODS: Between 1991 and 2006 a total of 73 women with liver metastases underwent surgery for ovarian cancer.
  • In 40 patients a liver resection was performed.
  • RESULTS: Residual tumor after surgery was by far the strongest predictor for outcome.
  • Median survival in patients with no residual tumor was 65 months, < 0.5 cm 29 months, 1cm 6 months.
  • This data clearly show that macroscopically complete surgical cytoreductive therapy improves long-term survival in patients with ovarian cancer and liver metastases.
  • Therefore, liver resection should be always discussed if complete resection is achievable and should be part of the multimodal strategy in advanced ovarian cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960822.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Watson RG, Muhale F, Thorne L, Yu J, O'Neil B, Hoskins JM, Myers MO, McLeod HL, Auman JT: Association of copy number variants in colorectal liver metastases with 5-fluorouracil resistance. J Clin Oncol; 2009 May 20;27(15_suppl):e14502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of copy number variants in colorectal liver metastases with 5-fluorouracil resistance.
  • : e14502 Background: Resistance to 5-fluorouracil (5-FU) represents a major contributor to cancer-related mortality in advanced colorectal cancer patients.
  • We assessed TYMS and TP copy number in colorectal liver metastases from untreated patients and patients treated with 5-FU in an effort to elucidate the underlying molecular mechanisms for 5-FU resistance.
  • METHODS: Liver metastases were procured from 59 patients who had received 5-FU within 6 months preceding liver resection (treated samples) and from 46 patients who had received no 5-FU treatment in the 6 months prior to their liver resections (untreated samples).
  • DNA copy number of TYMS and TP was evaluated in frozen colorectal liver metastases using quantitative real time PCR.
  • CONCLUSIONS: Colorectal liver metastases treated with 5-FU exhibit DNA copy variants that may reduce 5- FU's efficacy.
  • Our data suggest that these genetic alterations may have important implications for the management of advanced colorectal cancer patients with recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963535.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Oshima T, Yamamoto N, Sato T, Nagano Y, Fujii S, Kunisaki C, Shiozawa M, Akaike M, Rino Y, Masuda M, Imada T: Overexpression of EphA4 gene and reduced expression of EphB2 gene: Correlation with liver metastasis in colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15129
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of EphA4 gene and reduced expression of EphB2 gene: Correlation with liver metastasis in colorectal cancer.
  • This study examined the relations of EphA4 and EphB2 gene expression to clinicopathological factors, especially metastasis, in patients with colorectal cancer.
  • We studied surgical specimens of cancer tissue and adjacent normal mucosa obtained from 205 patients with untreated colorectal cancer.
  • The relative expression level of EphA4 mRNA was higher in the presence than in the absence of liver metastasis, whereas the relative expression levels of EphB2 mRNA were similar.
  • Analysis of the relations between clinicopathological features and gene expression showed that high expression of the EphA4 gene and low expression of the EphB2 gene correlated with liver metastasis.
  • Our results suggest that over-expression of the EphA4 gene and reduced expression of the EphB2 gene might promote liver metastasis in colorectal cancer.
  • Over-expression of the EphA4 gene and reduced expression of the EphB2 gene may thus be a useful predictor of liver metastasis in patients with colorectal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960831.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Han W, Kim H, Lee J, Lee K, Moon H, Ko E, Kim E, Yu J, Noh D: Value of preoperative staging of breast cancer patients using computed tomography to detect asymptomatic lung and liver metastasis. J Clin Oncol; 2009 May 20;27(15_suppl):1105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of preoperative staging of breast cancer patients using computed tomography to detect asymptomatic lung and liver metastasis.
  • : 1105 Background: Preoperative clinical staging in breast cancer patients is important to determine the most appropriate treatment plans and to predict prognosis for individual patients.
  • Identifying unexpected distant metastases in newly diagnosed breast cancer patients frequently alters initial treatment plans.
  • Routine imaging studies to detect lung or liver metastasis is not indicated in patients with early and operable breast cancer.
  • A recent study showed that routine use of chest radiograph and liver ultrasound does not provide much diagnostic benefit in early breast cancer patients.
  • METHODS: We aimed to investigate the value of preoperative computed tomography to detect asymptomatic liver and lung metastasis in breast cancer patients.
  • We performed preoperative CT for 667 breast cancer patients to detect lung and liver metastasis among 1,636 primary breast cancer patients who had been diagnosed and treated between January 2006 and December 2007 at Seoul National University Hospital.
  • RESULTS: CT showed abnormal findings (suspicious of metastasis or indeterminate nodules) in 78 patients (10.5%).
  • Among these, abnormal finding in 13 patients (1.7%) turned out to be true metastatic lesions.
  • There was no CT-detected lung or liver metastasis in patients with T1 tumor and 4 metastases in patients with T2 tumor.
  • There was no CT-detected lung or liver metastasis in patients with negative axillary lymph node metastasis.
  • When patients were classified according to the AJCC staging, CT-detected true metastatic lesions were only present in stage III patients (13 out of 173 patients, 7.5%).
  • The true metastatic lesions in lung or liver were all small sized nodules, ranging from 0.3cm to 1.2cm in largest diameters.
  • In seven patients, the CT-detected metastatic lesions were less than 1cm which is in contrast with the previous studies.
  • CONCLUSIONS: Our results demonstrated the lack of usefulness in performing routine CT exams to detect asymptomatic liver and lung metastasis in early breast cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962171.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Rojas Llimpe F, Di Fabio F, Ercolani G, Giampalma E, Serra C, Castellucci P, Pini S, Mutri V, Golfieri R, Pinto C, Martoni A: Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study). J Clin Oncol; 2009 May 20;27(15_suppl):e15010
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study).
  • : e15010 Background: The aim of the study was to define the specific diagnostic accuracy of different imaging techniques in patients (pts) with resectable colorectal cancer liver metastasis (CLMs).
  • METHODS: Consecutive pts with, potentially resectable CLMs afferent to the Multidisciplinary Liver Team of Bologna Sant'Orsola Malpighi Hospital performed, in the 3 weeks prior to liver surgery, computed tomography scan (CT), magnetic resonance diffusion-weighted (MR-DW), and liver contrast-enhanced ultrasonography (CEUS1).
  • Liver contrast-enhanced ultrasonography was also performed intra-operatively (CEUS2).
  • RESULTS: From December 2007 to December 2008, twenty-nine out of 50 pts enrolled in the PROMETEO study underwent liver resection.
  • The pt characteristics were: 18 (62%) males, 11 (38%) females; 18 (62%) synchronous metastasis, 11 (38%) metachronous metastasis; 15 (51.7%) neoadjuvant chemotherapy; 7 (24.1%) previous liver surgery; 3 (10.3%) previous loco-regional treatment.
  • Ninety-three liver lesions were resected; the median number lesions per patient was 2 (range 1- 10).
  • Five lesions at pathological examination were non-metastasis (1 hamartoma, 1 steatosis, 1 giant-cell reaction, 2 necrosis).
  • CONCLUSIONS: These results show that CT, CEUS1 and MR-DW have a good accuracy in the detection of liver metastasis in patients who are candidates for resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964437.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Chi Z, Cui C, Yuan X, Si L, Sheng X, Shen L, Guo J: Intra-arterial hepatic bio-chemotherapy for the treatment of melanoma patients with liver metastasis: A phase II clinical study. J Clin Oncol; 2009 May 20;27(15_suppl):e20014
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial hepatic bio-chemotherapy for the treatment of melanoma patients with liver metastasis: A phase II clinical study.
  • : e20014 Background: To investigate the efficacy and safety of hepatic intra-arterial infusion of cisplatin, fotemustine combined with systemic dacarbazine for the treatment of melanoma patients with liver metastasis.
  • METHODS: From 2005.7 to 2008.7, thirty-six melanoma patients with liver metastatic were enrolled.
  • Systemic dacarbazine (250mg/m<sup>2</sup> d1-5) and intra-arterial hepatic (i.a.h.) of cisplatin (75mg/m<sup>2</sup> d6) and fotemustine (100mg/m<sup>2</sup> d7) were given repeated for 4-weeks.
  • RESULTS: 27 of the 36 patients were evaluable, with mean cycle 2.16±1.19, one achieved CR, one PR and seven SD.
  • CONCLUSIONS: Intra-arterial hepatic chemotherapy show its efficacy and may prolong PFS in melanoma patients with liver metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Bouganim N, Kavan P, Eid M, Metrakos P, Chaudhury P, Batist G: Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study. J Clin Oncol; 2009 May 20;27(15_suppl):e15027
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study.
  • : e15027 Background: Colorectal liver metastases treated with perioperative chemotherapy were previously shown to increase progression free survival.
  • Given the survival benefit of bevacizumab in metastatic CRC, the aim of this study was to assess the efficacy and safety of bevacizumab based chemotherapy in the perioperative setting.
  • CONCLUSIONS: Bevacizumab-containing chemotherapy regimens in the peri-operative setting is effective in patients with colorectal liver metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964397.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Halama N, Michel S, Kloor M, Zoernig I, Pommerencke T, Schirmacher P, von Knebel-Döberitz M, Weitz J, Grabe N, Jäger D: Immune infiltrates in liver metastases of colorectal cancer and response to chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e15069
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune infiltrates in liver metastases of colorectal cancer and response to chemotherapy.
  • : e15069 Background: Colorectal cancer (CRC) is a major cause of death from cancer.
  • In primary colon cancer immune infiltrates in the tumor represent an important prognostic factor.
  • High densities of tumor infiltrating lymphocytes (TIL) were shown to be correlated with an improved survival in patients with primary CRC.
  • METHODS: Here the relation between infiltrates of immune cells in liver metastases of CRC and the response to chemotherapy (using immunohistochemical staining against CD8, GranB, FOXP3, CD45RO, etc.) was investigated.
  • Samples from 33 patients with metastasized colorectal cancer (samples from 22 patients were used as training set and samples from 11 patients as validation set) were analyzed.
  • RESULTS: The evaluation of positively stained TIL in the invasive margin of the liver metastasis allowed to predict response to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964498.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Mucciarini C, Bellentani S, Razzini G, Bernardini I, Artioli F, Iop A, Blanzieri S: The role of contrast-enhanced ultrasound in detection of liver metastases from colorectal cancer: A prospective monocentric study. J Clin Oncol; 2009 May 20;27(15_suppl):e15105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of contrast-enhanced ultrasound in detection of liver metastases from colorectal cancer: A prospective monocentric study.
  • : e15105 Background: Up to 15-25% of patients with colorectal cancer (CRC) will develop metacronous liver metastases during the follow up.
  • The management and prognosis of these patients depend heavily on the early detection of metastases.
  • The introduction of second generation ultrasound contrast agents have improved the ability of contrast-enhanced ultrasound (CEUS) in detecting and characterizing liver lesions, showing that its accuracy is comparable to that of spiral CT and MRI with a liver contrast agent, with a cost and a time saving.
  • We tested the sensitivity and specificity of CEUS in detecting liver metastases compared with the standard imaging modalities used in the follow up of CRC.
  • METHODS: We conducted a prospective study considering all patients with a diagnosis of CRC in high risk stage II, stage III or with a previous metastasectomy of the liver.
  • In order to detect possible metastases, the patients were followed with a follow-up schedule including a six-monthly ultrasonography alternated to an annual CT, and a six-monthly CEUS with SonoVue contrast agent for the first 3 years.
  • RESULTS: From January 1<sup>st</sup> to December 2008 we executed 60 CEUS, identifying thirteen suspected liver lesions.
  • 10/13 were confirmed metastases by CT, MRI or TC/PET.
  • CONCLUSIONS: The clinical value of CEUS as a reliable alternative to CT or MRI in characterizing focal liver lesions has been expressed in various documents and guidelines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964331.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Viudez A, Zárate R, Garrido M, Rodríguez J, Chopitea A, Fernández-Troconiz I, Pardo F, García-Foncillas J: Dose escalation of capecitabine in combination with biweekly cetuximab and hepatic arterial infusion (HAI) of oxaliplatin in patients with liver metastases of colorectal cancer: Preliminary clinical results. J Clin Oncol; 2009 May 20;27(15_suppl):e15080
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalation of capecitabine in combination with biweekly cetuximab and hepatic arterial infusion (HAI) of oxaliplatin in patients with liver metastases of colorectal cancer: Preliminary clinical results.
  • : e15080 Background: To determine the maximum-tolerated dose (MTD) and the doses-limiting-toxicities (DLT) of concurrent capecitabine and cetuximab plus HAI of oxaliplatin (LOHP) in patients with hepatic metastases from colorectal cancer (CCR).
  • Disease progression occurred in 15 pts (78.9%; 3 pts in liver only; 4 pts with extrahepatic metastases; 8 cases with both, hepatic and extrahepatic disease).
  • DLT and MTD were established in DL4 (two pts with diarrhoea grade IV with one of them with grade III HFS) Conclusions: Combination therapy with HAI LOHP plus concurrent capecitabine and cetuximab, can be safely administered to patients with liver metastases from CCR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964549.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Mahfouf H, Djeddi H, Belhadef S, Bouzid K, Bentabak K: Capecitabine combined with oxaliplatin (XELOX) as first-line chemotherapy in colorectal cancer with liver metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e15146
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine combined with oxaliplatin (XELOX) as first-line chemotherapy in colorectal cancer with liver metastases.
  • : e15146 Background: The combination of 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (I-OHP) was shown to be both more active against metastatic colorectal carcinoma and better tolerated.
  • METHODS: Chemotherapy-naive patients confirmed histologic colorectal cancer with liver metastases, adequate born morrow, renal and hepatic function, measurable diseases were considered eligible for the study.
  • Seven patients from 11 with objective response underwent major liver resection: 2 bisegmentectomy, 1 left lobectomy, 4 segmentectomy, and receive the same regimen of chemotherapy (Six cycles) as an adjuvant treatment and still alive without recurrence.
  • CONCLUSIONS: The combination of oxaliplatin and capecitabine is safe and has a promising activity in patients with liver metastatic colorectal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960868.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Malik H, Poston G: Do predictive scoring systems have any role in determining treatment strategy for colorectal liver metastases at the individual patient level? J Clin Oncol; 2009 May 20;27(15_suppl):e15104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do predictive scoring systems have any role in determining treatment strategy for colorectal liver metastases at the individual patient level?
  • : e15104 Background: the literature contains four prognostic scoring systems from large volume series predicting survival after resection for colorectal liver metastases.
  • Clearly, future developments in this field must incorporate advances in our understanding of tumor biology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964333.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Goere D Sr, Dsehais I, de Baere T, Boige V, Malka D, Bonnet S, Dromain C, Elias D, Ducreux M: Hepatic resection of initially unresectable liver metastases from colorectal cancer after hepatic arterial infusion of oxaliplatin and systemic 5-fluorouracil and leucovorin. J Clin Oncol; 2009 May 20;27(15_suppl):e15015
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection of initially unresectable liver metastases from colorectal cancer after hepatic arterial infusion of oxaliplatin and systemic 5-fluorouracil and leucovorin.
  • : e15015 Background: About 80% of patients (pts) presenting colorectal liver metastases (CRLM) are initially unresectable.
  • Efficacy of hepatic arterial infusion (HAI) of oxaliplatin with systemic 5-Fluorouracil and leucovorin (LV5FU2) in with unresectable CRLM was previously demonstrated.
  • Eighty-seven pts were selected from a prospective database Results: Hepatic arterial infusion was delivered after previous systemic chemotherapy failure in 69 pts (80%).
  • Main criterion for unresectability was massive liver involvement (80%).
  • After a median follow-up of 75 months [24-118], intra-hepatic recurrence occurred in 10 pts.
  • CONCLUSIONS: Hepatic artery infusion of oxaliplatin and systemic LV5FU2 increase the resectability rate in pts with advance CRLM even after previous systemic chemotherapy failure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964419.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Bechstein WO, Lang H, Köhne C, Parisi F, Raab HR, Frilling A, Konopke R, Weitz J, Stroszczynski C, Folprecht G: Resectability and agreement between surgeons: Review of CT and MR scan of the CELIM study: (Multicenter randomized trial of cetuximab/FOLFOX versus cetuximab/FOLFIRI in unresectable liver metastases. J Clin Oncol; 2009 May 20;27(15_suppl):4091
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resectability and agreement between surgeons: Review of CT and MR scan of the CELIM study: (Multicenter randomized trial of cetuximab/FOLFOX versus cetuximab/FOLFIRI in unresectable liver metastases.
  • : 4091 Background: Liver resection of patients with colorectal cancer liver metastasis (mets) may provide curative therapy.
  • The decision for resection is based on CT- or MRI scans and includes technical aspects (esp. remaining liver tissue) and prognostic factors (i.e. number of metastases).
  • METHODS: During two workshops, CT- or MRI scans at baseline (BL) and after 4 months treatment (follow-up, F-U) of CELIM-patients (pts) were presented to surgeons (surg.) who were blinded to each other, the time of investigation (BL or F-U) and clinical data.
  • Both, BL and F-U scans, were available for 75 pts (68% of study pts).
  • During the review, 24 pts changed from 'non-resectable' at BL to 'resectable' at F-U, 5 pts from 'resectable' to 'non-resectable', 29 pts remained 'non-resectable', and 17 pts 'resectable' (19 pts more resectable at F-U; chi-square: p=.021).
  • R0 resection was actually performed in 16/29 pts classified as 'resectable' (55%) and 13/54 pts not classified as 'resectable' (24%) according to presented BL- images.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Araujo L, Metzger Filho O, Gomes CA, Moitinho MV, Silva AM, Carcano FM, Noronha Júnior H: Clinical outcomes and predictive factors in patients with liver metastasis from breast cancer treated with gemcitabine and cisplatin (GC) salvage regimen. J Clin Oncol; 2009 May 20;27(15_suppl):e17568
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes and predictive factors in patients with liver metastasis from breast cancer treated with gemcitabine and cisplatin (GC) salvage regimen.
  • : e17568 Background: Liver metastasis (mets) from breast cancer is typically associated with poor prognosis.
  • GC is a good option, since patients (pts) have often failed anthracycline and taxane therapy and liver dysfunction may preclude these regimens.
  • METHODS: Retrospective study designed to evaluate the clinical outcomes and predictive factors in pts with metastatic breast cancer treated with GC, with special interest for liver mets.
  • Median age was 52.1 years, 33 pts had PS 0-1, 26 were hormone receptor (HR) negative, 32 had been treated with 3 or more chemotherapy (CT) regimens and 34 had liver mets.
  • OS was 4.0 mo (95% CI; 2.3-8.9) for pts with liver mets and 9.7 mo (95% CI; 6.9-12.9) for pts without liver mets (p = 0.03).
  • No factor showed correlation with OS in pts with liver mets, including age < 45 years (median OS [95% CI]: 2.8 mo [1.8-11.5] versus 4.5 mo [2.5-8.9]; p = 0.74), PS 0-1 (median OS [95% CI]: 7.3 mo [2.5-11.5] versus 2.8 mo [0.8-9.7]; p = 0.55), HR positivity (median OS [95% CI]: 7.3 mo [2.0-11.5] versus 5.9 mo [1.9-9.7]; p = 0.87), bilirubin level ≥ 5 times the superior limit of the normality (median OS [95% CI]: 5.9 mo [0.5-16.7] versus 4.5 mo [2.5-9.7]; p = 0.45), progression free interval after the previous CT ≤ 1 mo (median OS [95% CI]: 4.0 mo [2.0-9.7] versus 7.1 mo [2.5-14.7]; p = 0.93) and previous treatment with ≥ 3 CT regimens (median OS [95% CI]: 7.3 mo [1.0-11.0] versus 4.0 mo [2.0-9.7]; p = 0.93).
  • CONCLUSIONS: These data is in accordance with the literature concerning the dismal prognosis in liver mets from breast cancer and the clinical activity of GC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Kandioler D, Pilat N, Kappel S, Gruenberger T, Laengle F, Mittlboeck M, Herberger B, Kuehrer I, Jakesz R, Muehlbacher F: A prospective study of the interaction between p53 genotype and overall survival in patients with colorectal cancer liver metastases (CRCLM) with and without neoadjuvant therapy (oxaliplatin and capecitabine/5-FU): A p53 research group study. J Clin Oncol; 2009 May 20;27(15_suppl):e15003
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of the interaction between p53 genotype and overall survival in patients with colorectal cancer liver metastases (CRCLM) with and without neoadjuvant therapy (oxaliplatin and capecitabine/5-FU): A p53 research group study.
  • Unfortunately, there remains no clear evidence that p53 gene mutation affects cancer survival rates.
  • The groups did not differ in age, chronicity of CRCLM, staging and grading of the primary colorectal cancer.
  • Our data suggests an interaction between the p53 gene and chemotherapy in patients with colorectal liver metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964362.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Djedi H, Bouzid K: Capecitabine-based chemotherapy versus primary treatment for patients with advanced stages of undifferentiated nasopharyngeal carcinoma (UCNT): Preliminary results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e17049
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The overall objective response (CR+PR) was achieved in 96% of cases (25/26pts ), one patient had a stable disease.
  • One of the two patients with stage IVC had a complete response on hepatic metastasis after 3 cures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961741.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Yopp AC, Shia J, Allen PJ, DeMatteo RP, Jarnagin WR, Fong Y, Blumgart L, D'Angelica MI: Use of CXCR4 as a prognostic marker for disease-specific survival and pattern of recurrence following resection of hepatic colorectal metastases. J Clin Oncol; 2009 May 20;27(15_suppl):11081
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of CXCR4 as a prognostic marker for disease-specific survival and pattern of recurrence following resection of hepatic colorectal metastases.
  • : 11081 Background: Expression of the chemokine receptors CXCR4 and CCR7 has been associated with metastases and poor prognosis in primary tumors but their relevance in colorectal liver metastases (CLM) is unclear.
  • This study examines the relationship between tumor chemokine receptor expression, pattern of recurrence and outcome after resection of hepatic metastases.
  • METHODS: Eighty patients with metastases from colon or rectal primary tumors who underwent a R<sub>0</sub> partial hepatectomy from February 2002 to April 2004 were studied prospectively.
  • Immunohistochemical staining was performed on the formalin-fixed, paraffin-embedded tissues of hepatic metastases using antibodies specific for CXCR4, CXCL12 and CCR7.
  • Positive expression of CXCR4, CXCL12 and CCR7 was seen in 49 (61%), 23 (29%) and 48 (60%) of tumor specimens, respectively.
  • CCR7 and CXCL12 expression, hepatic artery infusion pump chemotherapy, systemic chemotherapy and site of primary disease did not influence DSS or RFS.
  • Fifty-three (68%) of the patients recurred; 11 with liver only recurrences, 25 with lung only recurrences and 18 with multiple sites of recurrences.
  • CONCLUSIONS: CXCR4 expression in colorectal hepatic metastases adds prognostic information with regards to DSS, RFS and patterns of recurrence and may play role in clinical decision making regarding chemotherapy and surgical interventions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963167.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Hasegawa J, Yoshida Y, Mizushima T, Fujii M, Mizuno H, Tamagawa K, Nezu R: Outcome of initially unresectable advanced and metastatic colorectal cancer patients treated with first-line mFOLFOX6 followed by surgical tumor removal of metastases: Preliminary results of a phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e15122
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of initially unresectable advanced and metastatic colorectal cancer patients treated with first-line mFOLFOX6 followed by surgical tumor removal of metastases: Preliminary results of a phase II trial.
  • : e15122 Objective: The aim of this study was to evaluate the efficacy and tolerability of treatment with mFOLFOX6 followed by surgical tumor removal in patients (pts) with initially unresectable liver metastases and/or extrahepatic disease from colorectal cancer (CRC).
  • Eligibility criteria defined pts with advanced and metastatic CRC deemed not optimally resectable. mFOLFOX6 (oxaliplatin 85 mg/m<sup>2</sup>, l-leucovorin 200 mg/m<sup>2</sup>, and fluorouracil [400 mg/m<sup>2</sup> bolus followed by 2,400mg /m<sup>2</sup> as a continuous 46-hour infusion]) was administered every 2 weeks for a maximum of 10 cycles.
  • Main unresectable lesions were liver metastases in 10 pts and extrahepatic disease in 16 pts.
  • In 16 of these 24 pts who achieved the disease control, surgical tumor removal was performed (resectability 61%).
  • The main reasons for initial unresectability in these 16 pts were the presence of liver metastases (6 pts), para-aortic lymph-node metastases (4 pts), carcinomatous peritonitis (4 pts), direct invasion to neighboring organ (2 pts).
  • At a median follow-up of 13 months (range 5 -21), 5 pts had relapsed after surgical tumor removal.
  • CONCLUSIONS: Our data suggest that mFOLFOX6 has a significant antitumor activity in pts with not only liver metastases but also extrahepatic disease from CRC, allowing for successful resection of disease in a portion of pts initially not judged to be optimally resectable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960842.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Jiao L, Apostolopoulos C, Jacob J, Johnson N, Tsim N, Habib N, Coombes R, Stebbing J: The anatomic localization of circulating tumor cells and the immediate impact of surgery and radiofrequency ablation. J Clin Oncol; 2009 May 20;27(15_suppl):e22004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The anatomic localization of circulating tumor cells and the immediate impact of surgery and radiofrequency ablation.
  • : e22004 Background: There are few data on the impact of immediate and differing surgical interventions on circulating tumor cells (CTCs), nor their compartmentalization or localization in different anatomic vascular sites.
  • METHODS: CTCs from consecutive patients with colorectal liver metastases were quantitated prior to and immediately after open surgery, laparoscopic resection, open radiofrequency ablation (RFA) or percutaneous RFA.
  • For individuals undergoing open surgery, either hepatic resections or open RFA, CTCs were examined in both systemic and portal circulation by measuring CTCs in samples derived from the peripheral vein, an artery, the portal vein and hepatic vein.
  • RESULTS: A total of 29 consecutive patients with colorectal liver metastases were included with a median age of 55 (range 30 - 88 years).
  • CTCs were localized to the hepatic portosystemic macrocirculation with significantly greater numbers than in the systemic vasculature.
  • CONCLUSIONS: Surgical resection of metastases but not RFA decreases CTC levels.
  • In patients with colorectal liver metastases, CTCs are localized to the hepatic (and probably pulmonary) macrocirculations.
  • This may explain why metastases in sites other than the liver and lungs, are infrequently observed in cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963174.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Glisson SD, LaRocca RV, Hargis JB, Cervera A, Goldsmith G, Cornell B, Repishti DD, Sunderland JE: A phase II clinical trial utilizing maximum medical and surgical cytoredutive treatments for patients with metastatic colorectal cancer to the liver. J Clin Oncol; 2009 May 20;27(15_suppl):e15130
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II clinical trial utilizing maximum medical and surgical cytoredutive treatments for patients with metastatic colorectal cancer to the liver.
  • Combination chemotherapy with surgical cytoreduction for patients with liver metastases are evaluated in a phase II clinical trial.
  • METHODS: Patients with newly diagnosed mCRC to the liver or recurrent CRC after 5FU failure were consented to receive further chemotherapy with at least irinotecan-based chemotherapy, oxaliplatin-based chemotherapy, and with the intention to treat the liver metastases with either RFA and/or liver resection between chemotherapy regimens whenever possible.
  • There were eleven patients who underwent RFA of at least one liver metastasis.
  • There were ten patients who underwent liver resection.
  • One patient underwent both RFA and liver resection at two different times.
  • CONCLUSIONS: OS was improved in mCRC patients or recurrent CRC patients who had potentially ablatable or resectable liver lesions at the time of their diagnosis and who were treated with available aggressive medical and surgical therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960910.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Kavan P, Bouganim N, Eid M, Metrakos P, Chaudhury P, Batist G: Safety of bevacizumab when given perioperatively for colorectal cancer with liver metastases: McGill University pilot study. J Clin Oncol; 2009 May 20;27(15_suppl):e15083
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety of bevacizumab when given perioperatively for colorectal cancer with liver metastases: McGill University pilot study.
  • : e15083 Background: Bevacizumab (BV) increases responses and survival rates when used with chemotherapy in metastatic colorectal cancer (CRC).
  • Current practice is to give peri-operative chemotherapy for resectable CRC liver metasases (LM).
  • All patients underwent liver surgery 6-8weeks post last dose of BV.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964553.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Cejas P, López-Gómez M, Madero R, De Castro J, Casado E, Belda C, Larrauri J, Barriuso J, González-Barón M, Feliú J: Concordance of K-Ras status between colorectal cancer (CRC) primaries and related metastatic samples considering clinicopathological features. J Clin Oncol; 2009 May 20;27(15_suppl):4053
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concordance of K-Ras status between colorectal cancer (CRC) primaries and related metastatic samples considering clinicopathological features.
  • : 4053 Background: K-Ras mutations in CRC primaries may predict resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, but we don´t know its behaviour in metastatic tissue.
  • 1) Evaluate the grade of concordance of K-Ras status between primary and related metastatic samples 2) Establish a correlation between k-ras status and individual clinicopathological features Methods: K-ras mutations were retrospectively analysed in primary tumours of 124 patients and 138 related metastatic sites.
  • Sites of metastases were liver (115 samples,83.3%) and lung (23 samples,16.7%).
  • We analyzed K-Ras point mutations in codons 12 and 13 by direct DNA sequencing from paraffin-embedded tumour and studied its relation with 13 clinicopathological features Results: K-Ras mutation was observed in 42(33.6%) primary tumours and in 52(39.1%) related metastatic sites, being the grade of concordance between primary and metastatic sites of 93% (95% CI: 97.5-88.3%).
  • Discordance was observed in 9 (7%) patients: in 2, K-Ras status was wild type in metastatic site and expressed a mutational pattern in the primary tumour; vice versa, in 7, the mutation status was detected in the metastases meanwhile primary tumour was wild type.
  • We also found statistically significative differences in mutation patterns regarding the site of the metastasic tissue: K-ras mutations were detected in 13 lung samples (61.9%) and in 39 liver samples (34.8%) (p=0.028).
  • No other relation with clinicopathological data was detected Conclusions: With this observational analysis, we confirm the high concordance (superior to 90%) between primary and related metastatic sites in terms of K-Ras status; for the first time, we have reported a higher mutational pattern in lung metastases than in liver disease, founds that may have important relevance regarding clinical/treatment decisions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961589.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Sobhani I, Roudot-Thoraval F, Mesli F, Landi B, Aparicio T, Louvet C, DesGuetz G, Mitry E: Outcome of colon cancer patients with synchronous metastases. J Clin Oncol; 2009 May 20;27(15_suppl):4029
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of colon cancer patients with synchronous metastases.
  • : 4029 Background: Metastatic colon cancer patients may undergo chemotherapy without colon surgery.
  • METHODS: Consecutive patients [N=228, mean age (sd) 64 (12) yrs, median follow-up 20 mths;84 females] treated in 6 teaching hospitals received chemotherapy for metastatic colonic cancer, either as the first step, or after surgery.
  • RESULTS: 105 patients with colon cancer and synchronous metastatsis underwent colon surgery prior to chemotherapy (68 males, mean age 64 yrs) when 123 patients were treated first by chemotherapy ± biotherapy (76 males, mean age 63 yrs).
  • By univariate analysis, following factors were significantly associated with PFS: surgery first 25.5 (18.6 - 32.5) vs chemotherapy first 18.3 (14.7 - 21.9) mths p = 0.006; curative surgery: yes 35.7 (29.6 - 41.8) vs no 18.4 (15.6 - 21.2) mths p < 0.001; tumour histological differentiation : no : 13.4 (6.2 - 20.6) vs well : 24.7 (20.4 - 29.1) mths p<0.001; synchronous metastases: liver only 25.5 (20.5 - 30.6) vs peritonea&nodes : 18.4 (10.6 - 26.1) vs pulmonary & other sites : 16.5 (14.7 - 18.3) mths p < 0.0001; need for colonic stent: yes 16.4 (9.3 - 23.5) vs no 23.9 (21.1 - 26.7) months p < 0.0001; antiangiogenic drug: yes 36.6 (28.7 - 44.5) vs no : 20.7 (18.3 - 23.1) p = 0.033.
  • CONCLUSIONS: Colon surgery before chemotherapy plus bevacizumab appears to be the more appropriate choice, and associated with longer PFS, especially for those patients with well differentiated tumours and synchronous liver metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Levi F, Innominato P, Poncet A, Moreau T, Iacobelli S, Focan C, Garufi C, Bjarnason G, Adam R, Giacchetti S, ARTBC Chronotherapy Group: Meta-analysis of gender effect for first-line chronomodulated 5-fluorouracil-leucovorin-oxaliplatin (ChronoFLO) compared with FOLFOX or constant infusion (conventional delivery, CONV) against metastatic colorectal cancer (MCC) in three international controlled phase III randomized trials (RT). J Clin Oncol; 2009 May 20;27(15_suppl):4112
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis of gender effect for first-line chronomodulated 5-fluorouracil-leucovorin-oxaliplatin (ChronoFLO) compared with FOLFOX or constant infusion (conventional delivery, CONV) against metastatic colorectal cancer (MCC) in three international controlled phase III randomized trials (RT).
  • Main prognostic factors were comparable in each RT according to gender and treatment arm (median age: 61y; PS=0, 46% pts; liver M, 85% pts; liver involvement >25%, 41% pts; lung M, 37% pts; CEA>10, 56% pts).
  • The rate of complete macroscopic resections of liver metastases (R0+R1) was 12.5% in men on chronoFLO vs 7.8-8.5% in men on CONV or in women on either schedule.
  • A complete histologic response of liver metastases was documented in 2.1% of the men on chronoFLO vs 0-1.1% in the other groups.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961226.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Conte P, Campone M, Pronzato P, Amadori D, Frank R, Schuetz F, Rea D, Wardley A, Britten C, Elias A: Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. J Clin Oncol; 2009 May 20;27(15_suppl):1081
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results.
  • Six pts were ER and PR negative, eight pts had liver metastasis, eight pts had lung metastasis, and two pts had central nervous system metastasis.
  • The second cohort is ongoing, eight pts have been enrolled (five in i.v. and three in oral), and no DLTs have been reported yet.
  • In the first cohort, two pts experienced tumor reduction of 29% (both had liver metastasis), and four pts received over eight cycles of the combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961216.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Aliberti C, Benea G, Tilli M, Fiorentini G: Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal carcinoma (CRC) adopting drug eluting beads preloaded with irinotecan (DEBIRI): Results of a phase II study on 82 patients. J Clin Oncol; 2009 May 20;27(15_suppl):4092
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal carcinoma (CRC) adopting drug eluting beads preloaded with irinotecan (DEBIRI): Results of a phase II study on 82 patients.
  • A suspension of polyvinyl-alcohol beads (DC Bead) preloaded with Irinotecan ( 81 TACE procedures with 2ml of microspheres preloaded with 100mgr of Irinotecan and 104 with 4ml loaded with 200mgr of Irinotecan) was delivered selectively into hepatic arteries.
  • Within 1 month after treatment, CT scan showed significant ( 75-100%) reduction of metastatic contrast enhancement in all lesions treated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961670.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Morris E, Thomas J, Forman D, Quirke P, Cottier B, Poston GJ: The need for a revised staging system of metastatic (M) colorectal cancer (CRC): Evidence from a national perspective on survival following surgically treated (HPX) liver metastases. J Clin Oncol; 2009 May 20;27(15_suppl):4099
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The need for a revised staging system of metastatic (M) colorectal cancer (CRC): Evidence from a national perspective on survival following surgically treated (HPX) liver metastases.
  • : 4099 Background: AJCC V.6 (2002) places all patients with MCRC beyond the lymph node basin of the primary tumor in a homogenous Stage 4.
  • Patients with inoperable hepatic MCRC can be made operable with curative intent with chemotherapy yet remaining in Stage 4.
  • METHODS: All patients between 1998-2001 undergoing surgery for CRC in England were identified via the national-linked cancer registry HES dataset.
  • Survival was calculated from the date of resection of each patient's primary colorectal tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Erinjeri JP, Deodhar A, Thornton RH, Allen PJ, Getrajdman GI, Brown KT, Sofocleous CT, Reidy DL: Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol; 2010 Jun;33(3):610-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution of hepatic encephalopathy following hepatic artery embolization in a patient with well-differentiated neuroendocrine tumor metastatic to the liver.
  • Hepatic encephalopathy is considered a contraindication to hepatic artery embolization.
  • We describe a patient with a well-differentiated neuroendocrine tumor metastatic to the liver with refractory hepatic encephalopathy and normal liver function tests.
  • The patient's mental status returned to baseline after three hepatic artery embolization procedures.
  • In patients with a primary or metastatic well-differentiated neuroendocrine tumor whose refractory hepatic encephalopathy is due to portosystemic shunting (rather than global hepatic dysfunction secondary to tumor burden), hepatic artery embolization can be performed safely and effectively.
  • [MeSH-major] Embolization, Therapeutic / methods. Hepatic Artery. Hepatic Encephalopathy / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Acrylic Resins / therapeutic use. Angiography. Contrast Media. Diagnosis, Differential. Gelatin / therapeutic use. Humans. Liver Function Tests. Male. Middle Aged. Tomography, X-Ray Computed. Ultrasonography

  • Genetic Alliance. consumer health - Hepatic encephalopathy.
  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. GELATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19756861.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Contrast Media; 0 / trisacryl gelatin microspheres; 9000-70-8 / Gelatin
  •  go-up   go-down


97. Strobel K, Bode B, Dummer R, Veit-Haibach P, Fischer DR, Imhof L, Goldinger S, Steinert HC, von Schulthess GK: Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma. Eur J Nucl Med Mol Imaging; 2009 Nov;36(11):1774-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melanoma compared to liver metastases from cutaneous melanoma.
  • PURPOSE: The objective of this study was to evaluate the value of (18)F-FDG PET/CT and S-100B tumour marker for the detection of liver metastases from uveal melanoma in comparison to liver metastases from cutaneous melanoma.
  • METHODS: A retrospective evaluation was conducted of 27 liver metastases in 13 patients with uveal melanoma (UM) (mean age: 56.8, range: 30-77) and 43 liver metastases in 14 patients (mean age: 57.9, range: 40-82) with cutaneous melanoma (CM) regarding size and FDG uptake by measuring the maximum standardized uptake value (SUV(max)).
  • In nine patients liver metastases were further evaluated histologically regarding GLUT-1 and S-100 receptor expression and regarding epithelial or spindle cell growth pattern.
  • RESULTS: Of 27 liver metastases in 6 of 13 patients (46%) with UM, 16 (59%) were FDG negative, whereas all liver metastases from CM were positive.
  • Liver metastases from UM showed significantly (p < 0.001) lower SUV(max) (mean: 3.5, range: 1.5-13.4) compared with liver metastases from CM (mean: 6.6, range: 2.3-15.3).
  • In four of six (66.7%) patients with UM and liver metastases S-100B was normal and in two (33.3%) increased.
  • All PET-negative liver metastases were detectable by morphological imaging (CT or MRI).
  • S-100B was abnormal in 13 of 14 patients with liver metastases from CM.
  • Histological work-up of the liver metastases showed no obvious difference in GLUT-1 or S-100 expression between UM and CM liver metastases.
  • The minority (36%) of patients with UM had extrahepatic metastases and the majority (86%) of patients with CM had extrahepatic metastases, respectively.
  • CONCLUSION: FDG PET/CT and serum S-100B are not sensitive enough for the detection of liver metastases from UM, whereas liver metastases from cutaneous melanoma are reliably FDG positive and lead regularly to increased S-100B tumour markers.
  • The reason for the lower FDG uptake in UM liver metastases remains unclear.
  • We recommend to perform combined contrast-enhanced PET/CT in order to detect FDG-negative liver metastases from UM.
  • [MeSH-major] Fluorodeoxyglucose F18. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Melanoma / pathology. Nerve Growth Factors / blood. S100 Proteins / blood. Skin Neoplasms / pathology. Uveal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Female. Humans. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Retrospective Studies. S100 Calcium Binding Protein beta Subunit. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19495748.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nerve Growth Factors; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. Wang AZ, Zhu ZZ, Cong WM: [Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr;25(2):168-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer].
  • OBJECTIVE: To investigate the possible association between the single nucleotide polymorphisms (SNPs) (C-8343G, C-1863T and R72P) in TP53 gene and susceptibility to liver metastases of colorectal cancer (CRC) in a Chinese population.
  • METHODS: The genotypes of each SNP in TP53 gene were determined by either TaqMan assays or PCR-based restriction fragment length polymorphism (RFLP) method in 121 colorectal cancer patients with liver metastases and sex-, age-matched 280 cases with nonmetastatic CRC as a control.
  • Odds ratios (ORs) for colorectal liver metastases and 95% confidence intervals (CIs) from unconditional logistic regression models were used to evaluate relative risks.
  • RESULTS: No significant association of C-8343G or C-1863T with colorectal liver metastases risk was observed.
  • However, the R allele of the TP53 R72P polymorphism was more frequently found in metastatic cases than in nonmetastatic cases (P= 0.037).
  • When compared with PP homozygotes, the ORs of metastases for RP heterozygotes was 2.21 (95% CI: 1.13-4.33), for RR homozygotes was 2.26 (95% CI: 1.03-4.94), and for carriers of the 72R allele (RP or RR genotype) was 2.22 (95% CI: 1.16-4.26).
  • Stratified analysis indicated that carrying the 72R allele had a more pronounced increase in colorectal liver metastases risk among patients with positive P53 expression tumors (OR= 3.28, 95% CI: 1.21-8.88), whereas no significantly increased metastases risk was found in patients with negative P53 expression tumors (OR= 1.37, 95% CI: 0.52-3.62).
  • CONCLUSION: The R allele of the TP53 R72P polymorphism may contribute to the etiology of liver metastases in CRC patients, particularly among those with positive P53 expression tumors.
  • Both TP53 C-8343G and C-1863T may be not associated with colorectal liver metastases risk.
  • [MeSH-major] Colorectal Neoplasms / complications. Colorectal Neoplasms / genetics. Genes, p53 / genetics. Liver Neoplasms / genetics. Liver Neoplasms / secondary. Polymorphism, Genetic / genetics


99. Patiutko IuI, Chuchuev ES, Kotel'nikov AG, Sagaĭdak IV, Badalian KhV: [Synchronous operations in metastatic cancer of the liver]. Khirurgiia (Mosk); 2006;(5):14-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous operations in metastatic cancer of the liver].
  • The resection of the liver has been performed in 661 patients including 154 (23.3%) cases of synchronous metastatic cancer of the liver.
  • Among the latter patients primary tumor was removed in one stage with liver resection in 56% cases.
  • Elderly age of the patients, multiple bilobular foci in the liver, size of the foci more than 10 cm, traumatic operations on the primary focus were not contraindications to synchronous operations.
  • Surgical treatment for colorectal cancer should be supplemented with adjuvant chemotherapy.
  • The long-term results demonstrate better survival after synchronous operations for colorectal cancer.
  • [MeSH-major] Liver Neoplasms / secondary. Liver Neoplasms / surgery. Surgical Procedures, Operative / methods


100. Hompes R, Fieuws S, Aerts R, Thijs M, Penninckx F, Topal B: Results of single-probe microwave ablation of metastatic liver cancer. Eur J Surg Oncol; 2010 Aug;36(8):725-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of single-probe microwave ablation of metastatic liver cancer.
  • The aim of this study was to evaluate the variability and reproducibility of single-probe MWA vs. radiofrequency ablation (RFA) of liver metastases smaller than 3cm in patients without underlying liver disease.
  • METHODS: Sixteen liver metastases were treated using MWA, and matched for size and localisation with 13 metastases treated by RFA.
  • CONCLUSION: Ablation diameters after single-probe MWA of metastatic liver tumours are highly variable and suboptimal.
  • [MeSH-major] Catheter Ablation / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Microwaves

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20605397.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00922181
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement